PICK1 lipid-coupled peptide inhibitors
Lipid-conjugated bivalent peptide ligands form higher-order oligomers to inhibit PICK1, addressing the challenge of severe side effects in existing glutamate system drugs and providing effective treatments for maladaptive plasticity-related diseases.
Patent Information
- Application Number
- JP2022553063
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-03-06
- Filing Date
- 2021-03-05
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2041-03-05
AI Technical Summary
Current drugs targeting the glutamate system for conditions like neuropathic pain, post-ischemic excitotoxicity, and drug addiction suffer from severe side effects, and there is a lack of effective treatments for maladaptive plasticity-related diseases due to the challenge of developing potent inhibitors for proteins like PICK1-PDZ domain.
Development of lipid-conjugated bivalent peptide ligands that form higher-order oligomeric structures upon binding to PICK1, enhancing potency and reducing side effects by targeting the PICK1 scaffold protein responsible for AMPA receptor trafficking.
The lipid-conjugated bivalent peptide ligands provide potent inhibitors of PICK1, effectively treating conditions such as neuropathic pain, post-ischemic excitotoxicity, and drug addiction with reduced side effects and improved pharmacokinetics.
Smart Images

Figure 0007948598000025 
Figure 0007948598000026 
Figure 0007948598000027
Abstract
Description
[Technical Field]
[0001] This invention relates to a lipid-conjugated divalent peptide ligand that binds to a protein (PICK1) that interacts with C kinase-1, thereby inhibiting PICK1. The invention further relates to the therapeutic and diagnostic use of the PICK1 inhibitor. [Background technology]
[0002] Synaptic plasticity functions as a molecular substrate for learning and memory. Glutamate-mediated synaptic release of glutamate specifically activates N-methyl-D-aspartate receptors (NMDARs) and α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors (AMPARs), both ligand-opening ion channels. Activation of these receptors allows for the influx of Na+ in AMPARs and Ca2+ in NMDARs. In disease states such as stroke and post-traumatic ischemia, neuropathic pain, and poisoning, abnormal synaptic stimulation leads to maladaptive plasticity, resulting in hypersensitivity of glutamatergic synapses through the expression of calcium-permeable (CP) AMPA-type glutamate receptors (CP-AMPARs).
[0003] While many disease conditions involve hyperactivation or hypersensitivity of the glutamate system, the only currently used drugs that target the glutamate system are NMDA receptor antagonists, such as ketamine, which is used as an anesthetic. The development of novel glutamate-targeting drugs has proven difficult due to common problems involving severe side effects. Diseases such as neuropathic pain, post-ischemic excitotoxicity, and drug intoxication currently lack effective treatments. Therefore, there is a need to address these conditions.
[0004] The protein that interacts with C kinase-1 (PICK1) is a PDZ domain-containing scaffold protein that plays a central role in synaptic plasticity. PICK1 is essential for AMPAR function, primarily through the regulation of AMPAR transduction. The PDZ domain of PICK1 directly interacts with the C-terminus of the GluA2 subunit of the AMPAR receptor (AMPAR) as well as with protein kinases A and C, thereby regulating AMPAR phosphorylation and surface expression, and in turn regulating synaptic plasticity by adjusting the effectiveness of individual synapses. PICK1 is an intracellular scaffold protein primarily involved in regulating protein transduction and cell migration by mediating and promoting protein-protein interactions (PPIs) via its PDZ domain. The central role of PICK1 in cells lies in its ability to bind and interact with numerous intracellular molecules, including various protein partners, as well as membrane phospholipids. PICK1 is a functional dimer with two PDZ domains adjacent to a central membrane-bound BAR domain that mediates dimerization.
[0005] Protein-protein interactions (PPIs) are essential for most biochemical and cellular processes and are often mediated by scaffolding and signaling complexes. One of the most abundant classes of human facilitators of PPIs is the family of postsynaptic thickening protein-95 (PSD-95) / disk-large / ZO-1 (PDZ) domains. In the postsynaptic thickening, PDZ domain proteins such as PICK1 dynamically regulate the surface expression and activity of glutamate receptors, thus presenting attractive drug targets for the treatment of diseases or disorders associated with maladaptive plasticity. However, developing sufficiently potent inhibitors for these targets has proven challenging.
[0006] Targeting of the PDZ domain of PSD-95 has been successfully attempted by using bivalent peptide ligands. PSD-95 contains more PDZ domains, including PDZ1 and PDZ2 which share ligand preference, leading to the idea of targeting both PDZ domains with bivalent ligands. The first bivalent inhibitor was proposed by Long, et al. (2003), which provided only marginal affinity for PSD-95 PDZ12. More successful bivalent peptide ligands were later developed (Bach et al. 2009).
[0007] Dimeric peptide ligands targeting PSD-95 were functionalized with fatty acids. The modification was found to confer improved plasma half-life and subcutaneous stability of the peptide without affecting the affinity for the PDZ domains (WO 2015 / 078477).
[0008] As described above, there is a high need to provide potent inhibitors of the PICK1-PDZ domain for the treatment of diseases or disorders associated with maladaptive plasticity. SUMMARY OF THE INVENTION
[0009] The present invention provides high-affinity peptide inhibitors against Protein Interacting with C Kinase-1 (PICK1). The present inventors have surprisingly found that attachment of a lipid to a bivalent peptide ligand of PICK1 can result in a significant improvement in potency. Such an improvement in potency is highly desirable to provide potent inhibitors of the PICK1-PDZ domain, which are required for development for the treatment of diseases or disorders associated with maladaptive plasticity. Without being bound by theory, the improvement in potency of the lipid conjugated to the bivalent peptide ligands of the present disclosure is believed to be the result of micelle formation, which in turn leads to the formation of higher-order oligomeric structures of PICK1 upon binding, thereby resulting in inhibition of PICK1. Such an improvement in potency could not have been foreseen from the current use of lipid conjugation, which provides improved pharmacokinetics.
[0010] By targeting PICK1, a scaffold protein responsible for the trafficking of AMPA receptors, the risk of potential side effects of the compound is reduced compared to directly targeting the receptors. The compounds of the present disclosure provide treatment for patients having conditions such as neuropathic pain, post-ischemic excitotoxicity, or drug addiction.
[0011] In a first aspect, the present disclosure provides a PICK1 inhibitor comprising a peptide moiety and a non-peptide moiety, wherein the peptide moiety comprises a) a first peptide comprising an amino acid sequence of the general formula: X1X2X3X4X5; and b) a second peptide comprising an amino acid sequence of the general formula: X1X2X3X4X5 (wherein X1 is H, N, F, or T, or is absent; X2 is W, S, E, or Y; or is absent; X3 is L, V, or I; X4 is K, I, or R; and X5 is V) consists of; the non-peptide moiety is: c) a linker connecting the first peptide to the second peptide, and d) a lipophilic aliphatic group comprises.
[0012] In a second aspect, the present disclosure relates to a) a first peptide comprising an amino acid sequence of the general formula: X1X2X3X4X5; b) a second peptide comprising an amino acid sequence of the general formula: X1X2X3X4X5; (wherein X1 is H, N, F, or T, or is absent; X2 is W, S, E, or Y; or is absent; X3 is L, V, or I; X4 is K, I, or R; and X5 is V) c) a linker connecting the first peptide to the second peptide, and d) Lipophilic aliphatic group This provides micelles containing a PICK1 inhibitor.
[0013] In a further embodiment, the Disclosure provides a pharmaceutical composition comprising a PICK1 inhibitor or micelle as disclosed herein.
[0014] In a further embodiment, PICK1 inhibitors, micelles, or pharmaceutical compositions as disclosed herein are provided for use as pharmaceuticals.
[0015] In a further embodiment, the Disclosure provides a method for providing prevention and / or treatment of a disease or disorder related to maladaptive plasticity in a subject, the method comprising administering a PICK1 inhibitor, micelle or pharmaceutical composition as disclosed herein.
[0016] In a further embodiment, a method for diagnosing breast cancer in a subject requiring it is provided, the method being: a. Step of obtaining tissue samples from the above subjects; b. A step of staining the sample with a PICK1 inhibitor containing a detectable portion as disclosed herein; c. A step of measuring the level of PICK1 in the sample; and d. Step of comparing the level of PICK1 in the sample with a healthy standard. Includes, The increased level of PICK1 in the sample suggests that the individual in question has breast cancer.
[0017] In a further embodiment, a method is provided for predicting the prognosis of a subject with breast cancer, the method being: a. Step of obtaining tissue samples from the above subjects; b. A step of staining the sample with a PICK1 inhibitor containing a detectable portion as disclosed herein; c. A step of measuring the level of PICK1 in the sample; and d. Step of comparing the level of PICK1 in the sample with a healthy standard. Includes, An increased level of PICK1 in the sample suggests a poor prognosis. [Brief explanation of the drawing]
[0018] [Figure 1] Concentration-dependent self-assembly of myr-NPEG4-(HWLKV)2 as shown by size exclusion chromatography (SEC). NPEG4-(HWLKV)2 was used as a control. [Figure 2] a) Small-angle X-ray scattering analysis using a concentration series of myr-NPEG4-(HWLKV)2 confirms the self-assembly of myr-NPEG4-(HWLKV)2 into a micelle structure. b) Paired distance distribution functions (PDDF) for different concentrations of myr-NPEG4-(HWLKV)2. c) Sample parameters derived from PDDF. Mw / Mwteo suggests higher-order assembly of myr-NPEG4-(HWLKV)2 in the range of 5 to 8 individual molecules. [Figure 3] Binding of oligomer myr-NPEG4-(HWLKV)2 to PICK1. Fluorescence polarization competitive binding curves of myr-NPEG4-(HWLKV)2 (Ki,app=3.0nM, SEM interval [2.3~3.8]nM, n=6), HWLKV (Ki,app=6998nM, SEM interval [4972~9849]nM, n=3), and NPEG4-(HWLKV)2 (Ki,app=179nM, SEM interval [169~189], n=6) using 5FAM-NPEG4-(HWLKV)2 (5nM relative to myr-NPEG4-(HWLKV)2 (5nM relative to myr-NPEG4-(HWLKV)2) or 5FAM-HWLKV (20nM relative to HWLKV) as tracers (error bars indicate SEM for n=3). [Figure 4] SEC elution profiles of PICK1 in a molecular ratio of PICK1:myr-NPEG4-(HWLKV)2 of 4:1, in the absence (gray) or presence (black) of myr-NPEG4-(HWLKV)2, respectively. The elution profiles clearly suggest the formation of higher-order oligomers. [Figure 5]Effect of single amino acid substitutions in DAT C5(HWLKV) on binding affinity. A library of 95 HWLKV peptides with single amino acid substitutions at positions X1-X5 in the HWLKV sequence was tested by fluorescence polarized binding in competition with fluorescently labeled HWLKV. Data are given as a magnification change compared to the reference peptide HWLKV (set to 1), where darker hues suggest an increase in affinity (up to 3x) and lighter hues suggest a decrease in affinity. White indicates binding breakdown, and a cross indicates an insoluble peptide. Peptides shown in % were insoluble in buffer and dissolved in 10% DMSO. [Figure 6] Fibre affinity changes measured using FP competition of linked peptide libraries combining single amino acid substitutions from previous single substitution screens. The screens suggest NSVRV / TSIRV as the optimal 5-mer sequence, EIRV / YIIV as the optimal 4-mer sequence, and IIV / IRV as the optimal 3-mer sequence. These sequences could not be predicted from the initial 5-mer sequence, HWLKV. x suggests an insoluble or unbound peptide. [Figure 7] Chemical structures of tested divalent PICK1 inhibitors having different PEGx linkers, either linked to the N-terminal amine of HWLKV (PEG0-(C5)2, PEG1-(C5)2, PEG2-(C5)2, PEG3-(C5)2, PEG4-(C5)2) or to the lysine (K) side-chain amine (ac-(HWLKPEG4V)2) of the sequence HWLKV, although they do not contain lipid residues. [Figure 8] Increased affinity of various PEG linker compounds directed towards purified PICK1 for monomer C5(HWLKV) peptides. [Figure 9a-c]a) Efficacy of myr-NPEG4-(HWLKV)2 for acute inflammatory pain. In vivo experiments will reveal the ability of myr-NPEG4-(HWLKV)2 to alleviate induced pain in a complete Freund's adjuvant model of inflammatory pain through multiple administration routes. a) sc administration, b) dose response of sc administration, 2 μmol / kg, 10 μmol / kg, and 50 μmol / kg, c) it administration. The dashed curve represents data from the contralateral left hind leg used as an internal control of the animals. All data are expressed as median ± SEM. Abbreviations: adm. = administration, BL = baseline, CFA = complete Freund's adjuvant, i.pl. = plantar, it = intrathecal, sc = subcutaneous. [Figure 10] Efficacy of myr-NPEG4-(HWLKV)2 for neuropathic pain. In vivo experiments reveal the ability of myr-NPEG4-(HWLKV)2 to alleviate induced pain in a neuropathic SNI model of pain. The dashed curve represents data from the contralateral left hind leg used as an internal control in the animals. All data are expressed as median ± SEM. Abbreviations: PWT = Paw Retraction Threshold, SNI = Segmental Injury. [Figure 11] Mice were subjected to SNI surgery, and 9 days after surgery, a decrease in the threshold response to von Frey filaments in the ipsilateral hind paw was confirmed by von Frey filaments in accordance with the neuropathic pain state. On day 9, mice were treated with 10 μmol / kg of NPEG4-(HWLKV)2 (gray) without lipidization, which did not induce a significant increase in the pain withdrawal threshold. For comparison, the response to 10 μmol / kg myr-NPEG4-(HWLKV)2 is shown from Figure 10 (black dashed line). All data are expressed as median ± SEM. Abbreviations: PWT = paw withdrawal threshold, SNI = partial nerve injury. [Figure 12]Effect of myr-NPEG4-(HWLKV)2 on chronic pain one year later. Mice were subjected to SNI surgery, and two days after surgery, a decrease in the threshold response to the von Frey filament of the ipsilateral hind leg was confirmed by von Frey filament using monthly observations for one year (data not shown). After 52 weeks, mice were treated with 10 μmol / kg myr-NPEG4-(HWLKV)2, which produced a very significant relief of PWT in 5 hours. All data are expressed as median ± SEM. Abbreviations: PWT = paw retraction threshold, SNI = partial nerve injury. [Figure 13] Efficacy of myr-NPEG4-(HWLKV)2 for diabetic neuropathy. Diabetes (STZ model) was induced in mice by a single IP injection of 200 μg / mL streptozocin solution, and blood glucose was tested pre-injection and 7 days post-injection. Thirteen days after surgery, a decrease in the threshold response to von Frey filaments in the ipsilateral hind paw was confirmed by von Frey filaments corresponding to diabetic neuropathy. Sc injection of myr-NPEG4-(HWLKV)2 showed a dose-dependent increase in PWT with efficacy similar to pregabalin. All data are expressed as median ± SEM. Abbreviations: PWT = paw retraction threshold, STZ = streptozocin. [Figure 14] Efficacy of PDZ-binding motif variants. Mice were i.pl. injected with 50 μL of CFA into the right hind paw. Mice were sc-injected with myr-NPEG4 peptide with C5 sequence substitution at 0.4 μmol / kg on day 2 and 2 μmol / kg on day 5, as shown. Treatment with 0.4 μmol / kg of myr-NPEG4-(NSVRV)2 significantly increased PWT, while myr-NPEG4-(HWLKV)2 and myr-NPEG4-(SVRV)2 at 2 μmol / kg significantly increased PWT. At 2 μmol / kg, myr-NPEG4-(NSVRV)2 did not dissolve sufficiently. All data are expressed as median ± SEM. Abbreviations: PWT = paw retraction threshold, CFA = complete Freund's adjuvant. [Figure 15]Efficacy of myr-NPEG4-(HWLKV)2 in alleviating spontaneous pain. Mice were i.pl. injected with 50 μL of CFA into their right hind leg before receiving a single injection of myr-NPEG4-(HWLKV)2 (30 μmol / kg) in saline in a striped chamber and in the gray chamber of the apparatus shown on the left. On a different day, chamber preference was determined by the time spent in each chamber. CFA-injected mice spent significantly longer in the chamber injected with myr-NPEG4-(HWLKV)2, demonstrating relief of spontaneous pain. Naive mice (not treated with CFA) did not show site preference for a single dose of myr-NPEG4-(HWLKV)2. [Figure 16] Dose-dependent plasma exposure of myr-NPEG4-(HWLKV)2. Myr-NPEG4-(HWLKV)2 was administered via Sc to mice at three different doses as shown, and plasma exposure at different times was measured by LC-MS. Plasma concentration peaks reached 1 hour post-injection in a dose-dependent manner and decreased linearly kinetically, but did not show life extension compared to the non-lipidized peptide Tat-NPEG4-(HWLKV)2. [Figure 17] Solubility of myr-NPEG4-(HWLKV)2. Photograph of myr-NPEG4-(HWLKV)2 dissolved in PBS at 130 mM (250 mg / ml). [Figure 18] Results from efficacy studies of different compounds of the present invention in an animal model of inflammatory pain. Mice were injected i.pl. with 50 μL of CFA into the right hind leg. Two to five days after CFA injection, mice were sc-injected with X-NPEG4-(HWLKV)2 having a lipid substituent (X) at 2 μmol / kg as shown. All data are expressed as median ± SEM. Abbreviations; PWT = paw retraction threshold, CFA = complete Freund's adjuvant. A: unsaturated fatty acids and fatty diacides. B: fatty acid length. C: amino acid adducts and cholesterol. [Figure 19]Efficacy of mPD5 for thermal hypersensitivity. Mice were i.pl. injected with 50 μL of CFA into the right hind leg. Three days after CFA injection, a decrease in PWL in response to laser beam stimulation in the Hargreaves test confirmed thermal hypersensitivity. Injection of 10 μmol / kg (10 μl PBS / g) of myr-NPEG4-(HWLKV)2(mPD5) into mice resulted in a significant increase in PWL in the CFA-injected (ipsilateral) leg without affecting the PWL of the healthy (contralateral) leg. PBS injection did not affect PWL in either leg in n=6 mice / group. All data are expressed as median ± SEM. Abbreviations: PWT = paw withdrawal latency period, CFA = complete Freund's adjuvant. [Modes for carrying out the invention]
[0019] definition In this specification, non-peptides refer to a subset of PICK1 inhibitors that do not contain peptides. Peptides are understood to contain two or more α- or β-amino acids linked via amide bonds (including multiple). Therefore, non-peptides refer to compounds that do not contain two or more α- or β-amino acids linked via amide bonds (including multiple). A non-peptide moiety may contain a single amino acid.
[0020] In this specification, lipophilic aliphatic group refers to an aliphatic group having lipophilic characteristics. It may include an aliphatic chain or aliphatic ring. In the terminology used herein, lipid refers to such a lipophilic aliphatic group. The lipophilic aliphatic group may include functional groups that may be used for the attachment of lipophilic aliphatic groups to, for example, an NPEG linker to form the PICK1 inhibitors of this disclosure. Examples of lipophilic aliphatic groups include, but are not limited to, fatty acids, gonans, sterols, and steroids.
[0021] In this specification, divalent refers to a compound comprising two peptide ligands capable of coordinating, such as those that bind to a protein, such as PICK1, and containing two sites for coordination. A divalent peptide ligand may be a compound comprising two peptide ligands that are conjugated via a linker, such as forming a peptide dimer, as referred to herein. Therefore, divalent peptide ligands such as those disclosed herein may also be called dimeric peptide ligands.
[0022] In this specification, a functional group refers to a chemical group present in a compound. Functional groups include reactivity, such as being nucleophilic or electrophilic, and can be used to conjugate the compound to other compounds. Examples of functional groups include, but are not limited to, carboxylic acids, alcohols, and amines.
[0023] In this specification, micelle structure or micelle refers to the arrangement of a PICK1 inhibitor. When the term is used herein, a micelle has an arrangement in aqueous solution in which the nonpolar tail faces inward and the polar head faces outward (Example 3).
[0024] In this specification, turning radius (R g The radius of rotation refers to the root mean square distance from the axis of rotation of the object to the various particles of the object. The radius of rotation is therefore a measure of the size of the object.
[0025] In this specification, "detectable portion" refers to a portion that produces a detectable signal. Conventional portions known to those skilled in the art for detection may include fluorescent phores, chromophores, radioisotopes, or enzymes.
[0026] In this specification, amino acids constituting proteins are named using either one-letter or three-letter codes in accordance with the recommendations of IUPAC; see, for example, http: / / www.chem.qmw.ac.uk / iupac. Unless otherwise specified, amino acids may be D-type or L-type. In preferred embodiments, the amino acids of this disclosure are L-amino acids.
[0027] In this specification, α-carboxylic acid refers to a carboxylic acid conjugated to the α-carbon of an amino acid.
[0028] In this specification, α-amine refers to an amine conjugated to the α-carbon of an α-amino acid. In this specification, β-amine refers to an amine conjugated to the β-carbon of a β-amino acid.
[0029] Here, the ethylene glycol portion refers to the structural unit that makes up the PEG or NPEG linker. The more technical name for the "ethylene glycol portion" is "oxyethylene," and the chemical formula for that unit is shown here:
[0030] [ka]
[0031] PEG, polyethylene glycol; PEG is a compound of C 2n+2 H 4n+6 O n+2 and repeating structure:
[0032] [ka]
[0033] It is an ethylene glycol polymer having, In the formula, PEG xPEG4 refers to a PEG linker having x repeating ethylene glycol units, for example, a polymer with 4 ethylene glycol moieties (x=4). PEG0 refers to a linker having x=0, and contains two propionic acid molecules covalently bonded by an ether bond across the C3 carbon of each propionic acid moiety. Such a structure is also referred to herein as PEG0 (Figure 7), and is given by formula (III):
[0034] [ka]
[0035] It has a structure based on the following.
[0036] NPEG is a linker species described herein, derived from the classical PEG linker, in which one or more of the skeletal oxygen atoms are replaced by nitrogen atoms. x NPEG4 refers to an NPEG linker having x repeating ethylene glycol units, for example, a polymer with 4 ethylene glycol moieties (x=4), where one or more of the skeletal oxygen atoms are replaced by nitrogen atoms. NPEG0 refers to a linker having x=0 as defined above, where the ether is replaced by an amine.
[0037] PDZ is an acronym formed from the first letters of the three proteins discovered to share domain postsynaptic thickening protein-95 (PSD-95), Drosophila homologous disc large tumor suppressor (DlgA), and closure zone-1 protein (zo-1). The PDZ domain is a common structural domain of 80-90 amino acids found in signaling proteins. Proteins containing the PDZ domain often play a crucial role in anchoring receptor proteins within the membrane to cytoskeletal components.
[0038] Amide bonds are formed by the reaction between a carboxylic acid and an amine (by the accompanying removal of water). When the reaction occurs between two amino acid residues, the resulting bond is known as a peptide linkage (peptide bond).
[0039] Ester bonds are formed by a reaction between a carboxylic acid and an alcohol (through the accompanying removal of water).
[0040] The Von Frye test evaluates contact sensitivity with Von Frye filaments. These filaments are applied to the underside of the feet after the mouse has settled into a comfortable position within a restricted area with a perforated floor. The filaments are calibrated to flex when a set force is applied to the foot. The filaments are presented in increasing stiffness until a retraction of the foot is detected.
[0041] The absence of an amino acid should be understood as the amino acid residues directly adjacent to the non-existent amino acid being directly linked to each other by conventional amide bonds.
[0042] AMPAR, also known as the AMPA receptor, AMPA-type glutamate receptor, or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor, is an ion channel transmembrane receptor for glutamate that mediates fast synaptic transmission in the central nervous system (CNS). PICK1 interacts with AMPAR via its PDZ domain.
[0043] Chemical structure of divalent PICK1 inhibitors This disclosure provides a PICK1 inhibitor comprising a divalent peptide ligand capable of binding to PICK1, wherein the divalent peptide ligand is further conjugated to a lipid. The lipid conjugated to the divalent peptide ligand provides a very potent inhibitor of PICK, which can be used for the treatment of diseases or disorders associated with maladaptive plasticity.
[0044] In one embodiment, a PICK1 inhibitor is provided that includes a peptide portion and a non-peptide portion, wherein the peptide portion is a) A first peptide containing the amino acid sequence of general formula: X1X2X3X4X5; and b) A second peptide containing the amino acid sequence X1X2X3X4X5 in general formula. (In the formula, X1 is either H, N, F, or T, or does not exist; X2 is W, S, E, or Y; or it does not exist; X3 is L, V, or I; X4 is K, I, or R; and X5 is V. Composed of; The non-peptide portion is: c) A linker that links the first peptide to the second peptide, and d) Lipophilic aliphatic group Includes.
[0045] In one embodiment, a PICK1 inhibitor is provided that includes a peptide moiety and a non-peptide moiety, wherein the peptide moiety is a) General formula: A first peptide consisting of an amino acid sequence of X1X2X3X4X5; and b) A second peptide consisting of the amino acid sequence X1X2X3X4X5 in general formula. Composed of; (In the formula, X1 is either H, N, F, or T, or does not exist; X2 is W, S, E, or Y; or it does not exist; X3 is L, V, or I; X4 is K, I, or R; and X5 is V. The non-peptide portion is: c) A linker that links the first peptide to the second peptide, and d) Lipophilic aliphatic group Includes.
[0046] In one embodiment, the PICK1 inhibitor is given by formula (I):
[0047] [ka]
[0048] It has the general structure of, During the ceremony, Z is a single bond or a single amino acid; n is an integer between 0 and 12; p is an integer between 0 and 12.
[0049] Peptide portion The peptide ligand portion of the PICK1 inhibitor of this disclosure provides the binding of the PICK1 inhibitor to the PDZ domain of PICK1. The peptide portion of the PICK1 inhibitor of this disclosure comprises a first and a second peptide. In one embodiment, the first and second peptides are identical. In a separate embodiment, the first and second peptides are different from each other. In one embodiment, the first and second peptides are linked via a linker to form a divalent peptide ligand.
[0050] In one embodiment, the first and / or second peptide is selected from the group consisting of HWLKV (SEQ ID NO: 54), FEIRV (SEQ ID NO: 34), NSIIV (SEQ ID NO: 5), NSVRV (SEQ ID NO: 8), NSLRV (SEQ ID NO: 53), NSIRV (SEQ ID NO: 6), NYIIV (SEQ ID NO: 13), NYIRV (SEQ ID NO: 14), TSIRV (SEQ ID NO: 18), YIIV (SEQ ID NO: 49), SVRV (SEQ ID NO: 44), EIRV (SEQ ID NO: 46), LRV, IIV, VRV, and IRV.
[0051] In one embodiment, the first and / or second peptide is selected from the group consisting of HWLKV, NSVRV, NSLRV, NSIRV, TSIRV, EIRV, YIIV, IIV, VRV, and IRV.
[0052] In one embodiment, the first and / or second peptide is selected from the group consisting of NSVRV, NSLRV, NSIRV, TSIRV, EIRV, YIIV, IIV, VRV, and IRV.
[0053] In one embodiment, the first and / or second peptide is selected from the group consisting of HWLKV, FEIRV, NSIIV, NSVRV, NSLRV, NSIRV, YIIV, SVRV, VRV, and LRV.
[0054] In one embodiment, the first and / or second peptide is selected from the group consisting of FEIRV, NSIIV, NSVRV, NSLRV, NSIRV, YIIV, SVRV, VRV, and LRV.
[0055] In one embodiment, the first and / or second peptide is HWLKV, NSVRV, or NSIRV.
[0056] In one embodiment, the first and / or second peptide is HWLKV.
[0057] In one embodiment, the first and / or second peptide comprises an amino acid sequence of general formula: X1X2X3X4X5, where: X1 is either N, F, or T, or does not exist; X2 is S, E, or Y; or it does not exist; X3 is V, L, or I; X4 is I or R; and X5 is V.
[0058] In one embodiment, the first and / or second peptide comprises an amino acid sequence of general formula: X1X2X3X4X5, where: X1 is either N, T, or does not exist; X2 is S, E, or Y; or it does not exist; X3 is V, L, or I; X4 is I or R; and X5 is V.
[0059] In one embodiment, the first and / or second peptide comprises an amino acid sequence of general formula: X1X2X3X4X5, where: X1 is either N, F, or does not exist; X2 is S, E, or Y; or it does not exist; X3 is V, L, or I; X4 is I or R; and X5 is V.
[0060] In one embodiment, the first and / or second peptide includes an amino acid sequence having a length of 3 to 15 amino acids, for example, 3 to 14 amino acids, for example, 3 to 13 amino acids, for example, 3 to 12 amino acids, for example, 3 to 11 amino acids, for example, 3 to 10 amino acids, for example, 3 to 9 amino acids, for example, 3 to 8 amino acids, for example, 3 to 7 amino acids, for example, 3 to 6 amino acids, for example, 3 to 5 amino acids.
[0061] In a preferred embodiment, the first and / or second peptide includes an amino acid sequence having an amino acid length in the range of 3 to 5, for example, having an amino acid length of 3, for example, having an amino acid length of 4, for example, having an amino acid length of 5.
[0062] As shown in Example 12 and Figure 14 of this disclosure, PICK1 inhibitors containing peptide moieties consisting of first and second peptides having 5, 4, or 3 amino acid lengths demonstrate efficacy in pain relief, such as the relief of inflammatory pain.
[0063] Similarities or higher affinity to PICK1 have been previously demonstrated for longer peptides, including sequences of the first and / or second peptides of this disclosure (International Publication No. 2020 / 083905).
[0064] Non-peptide portion The PICK1 inhibitors of this disclosure include a non-peptide moiety. The non-peptide moiety of the PICK1 inhibitor includes a linker that combines a first and a second peptide to form a divalent peptide ligand. The non-peptide moiety further includes a lipid which may be conjugated to the linker. In one embodiment, the lipid is directly linked to the nitrogen atom of the linker.
[0065] In a separate embodiment, the non-peptide moiety further comprises a single amino acid. As defined above, the presence of a single amino acid in the non-peptide moiety is understood not to introduce a peptide into the non-peptide moiety. As defined above, a peptide is understood to comprise two or more α- or β-amino acids linked via an amide bond. The presence of a single amino acid does not introduce such a peptide as defined. In one embodiment, the single amino acid present in the non-peptide moiety functions to provide a handle for the attachment of a detectable moiety.
[0066] Linker In one embodiment, the linker is an NPEG linker. The NPEG linker may contain ethylene glycol moieties ranging from 0 to 24 in which one or more backbone oxygen atoms are replaced by nitrogen atoms, for example, ethylene glycol moieties ranging from 0 to 20 in which one or more backbone oxygen atoms are replaced by nitrogen atoms, for example, in the range of 0 to 16, for example, in the range of 0 to 14, for example, in the range of 0 to 12, for example, in the range of 0 to 10, for example, in the range of 0 to 8, for example, in the range of 0 to 6, for example, in the range of 0 to 4, for example, in the range of 0 to 2. Preferably, the NPEG linker contains 4 ethylene glycol moieties in which one or more backbone oxygen atoms are replaced by nitrogen atoms. In one embodiment, the NPEG linker contains 3 ethylene glycol moieties in which one or more backbone oxygen atoms are replaced by nitrogen atoms. In one embodiment, the NPEG linker contains 2 ethylene glycol moieties in which one or more backbone oxygen atoms are replaced by nitrogen atoms. In one embodiment, the NPEG-linker comprises one ethylene glycol moiety in which one or more skeletal oxygen atoms are replaced by nitrogen atoms. In one embodiment, the NPEG-linker comprises 0 ethylene glycol moieties in which one or more skeletal oxygen atoms are replaced by nitrogen atoms, i.e., the linker has a PEG0 structure as disclosed in Figure 7, in which oxygen atoms are replaced by nitrogen atoms. As defined above, the NPEG0 linker refers to a linker having x=0 and comprising two propionic acid moieties combined in an amine bond via the C3 carbon of each propionic acid moiety. In one embodiment, the linker is of formula (III),
[0067] [ka]
[0068] It has a structure based on the following.
[0069] In one embodiment, the linker is an NPEG linker. The NPEG linker may include ethylene glycol moieties in the range of 1 to 24 in which one or more skeletal oxygen atoms are replaced by nitrogen atoms, for example, ethylene glycol moieties in the range of 1 to 20, for example, in the range of 1 to 16, for example, in the range of 1 to 14, for example, in the range of 1 to 12, for example, in the range of 1 to 10, for example, in the range of 1 to 8, for example, in the range of 1 to 6, for example, in the range of 1 to 4, for example, in the range of 1 to 2, in which one or more skeletal oxygen atoms are replaced by nitrogen atoms.
[0070] One or more nitrogen atoms of the NPEG linker may be located at any position along the NPEG linker, for example, in the center of the NPEG linker or toward one end of the NPEG linker.
[0071] In one embodiment, one of the skeletal oxygen atoms in the NPEG-linker is replaced with a nitrogen atom.
[0072] The NPEG linker contains a functional group at each end and is provided for conjugation to the first and second peptides. In one embodiment, the NPEG linker contains a carboxylic acid at each end. The carboxylic acid of the NPEG linker may be bonded to the N-terminuses of the first and second peptides, providing linker conjugation to the first and second peptides via an amide bond.
[0073] lipophilic aliphatic group The non-peptide portion of the PICK1 inhibitors of this disclosure includes lipids. The lipids may be directly coupled to the linker or coupled to the linker via a single amino acid.
[0074] The lipids in this disclosure are lipophilic aliphatic groups. The lipophilic aliphatic groups present in the non-peptide portion of the PICK1 inhibitors in this disclosure may be aliphatic chains or aliphatic rings.
[0075] In one embodiment, the lipophilic aliphatic group is an aliphatic chain. The aliphatic chain may be a branched or unbranched chain. The aliphatic chain may be a saturated or unsaturated chain.
[0076] In one embodiment, the lipophilic aliphatic group is an aliphatic ring. The aliphatic ring may comprise a gonane structure such as a sterol. Alternatively, the aliphatic ring may comprise a steroid such as cholesterol. In Example 16, it is shown that constructs bearing cholesterol have activity in animal models of pain. Preferably, the cholesterol moiety is linked to N-PEG via an amino acid such as asparagine, for example beta-Asp.
[0077] In one embodiment, the lipophilic aliphatic group present in the non-peptide portion of the PICK1 inhibitor of the present disclosure further comprises a functional group such as a carboxylic acid, an alcohol or an amine. Said functional group provides conjugation of the lipophilic aliphatic group to the rest of the PICK1 inhibitor, such as to the linker directly or to the linker via a single amino acid.
[0078] In one embodiment, the lipophilic aliphatic group comprises an alcohol.
[0079] In one embodiment, the lipophilic aliphatic group comprises a carboxylic acid.
[0080] In one embodiment, the lipophilic aliphatic group is an aliphatic chain comprising a carboxylic acid, and is thus a fatty acid.
[0081] The lipophilic aliphatic group is C4 to C 26 may be a fatty acid. The lipophilic aliphatic group may be a saturated fatty acid or an unsaturated fatty acid. In one embodiment, the lipophilic aliphatic group is C 16 fatty acid or C 18 fatty acid.
[0082] In one embodiment, the lipophilic aliphatic group includes carbon atoms in the range of 4 to 26, for example, in the range of 4 to 24, for example, in the range of 4 to 22, for example, in the range of 4 to 20, for example, in the range of 4 to 18, for example, in the range of 4 to 16, for example, in the range of 4 to 14, for example, in the range of 4 to 12, for example, in the range of 4 to 10, for example, in the range of 4 to 8, for example, in the range of 4 to 6.
[0083] In one embodiment, the lipophilic aliphatic group includes carbon atoms in the range of 4 to 26, for example, in the range of 6 to 26, for example, in the range of 8 to 26, for example, in the range of 10 to 26, for example, in the range of 12 to 26, for example, in the range of 14 to 26, for example, in the range of 16 to 26, for example, in the range of 18 to 26, for example, in the range of 20 to 26, for example, in the range of 22 to 26, for example, in the range of 24 to 26.
[0084] In one embodiment, the lipophilic aliphatic group includes carbon atoms in the range of 4 to 26, for example, in the range of 6 to 24, for example, in the range of 8 to 22, for example, in the range of 10 to 20, for example, in the range of 12 to 18, for example, in the range of 14 to 18, for example, in the range of 14 to 16, or 16 to 18 carbon atoms.
[0085] In one embodiment, the lipophilic aliphatic group is selected from the group consisting of acetic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, margaric acid, stearic acid, arachidonic acid, behenic acid, lignoceric acid, cerotic acid, caproleic acid, lauroleic acid, myristoleic acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, gadoleic acid, and erucic acid. In a preferred embodiment, the lipophilic aliphatic group is selected from the group consisting of capric acid, lauric acid, myristic acid, palmitic acid, margaric acid, and stearic acid. In a more preferred embodiment, the lipophilic aliphatic group is myristic acid.
[0086] In embodiments where the lipophilic aliphatic group is a fatty acid moiety, it can be saturated or unsaturated in a cis or trans configuration. Example 16 shows that for a C14 fatty acid moiety, the unsaturated (cis or trans) and saturated moieties have similar effects in vivo. In one embodiment, the fatty acid moiety is polyunsaturated, such as having one, two, or three double bonds. In some embodiments, one double bond is located at the n-3 or n-6 position.
[0087] The fatty acid moiety may be modified by having an additional functional group at the end opposite the carboxylic acid group. Such a functional group may be an additional carboxylic acid, alcohol, ketone, or aldehyde. Example 16 shows that the lipophilic aliphatic group may contain a terminal carboxylic acid and is effective in an animal model of pain.
[0088] In one embodiment, the lipophilic aliphatic group is myristic acid, also known herein as myristoyl or myr.
[0089] In one embodiment, the lipophilic aliphatic group is selected from the group consisting of myristic acid, palmitic acid, stearic acid, docosahexaenoic acid (DNA), and cis-9-octadecenoic acid.
[0090] In one embodiment, the lipophilic aliphatic group is a diacid, such as tetradecanediic acid, hexadecanedioic acid, or octadecanediic acid.
[0091] Voluntary selection of amino acids The non-peptide portion may further contain a single amino acid. Such a single amino acid present in the non-peptide portion may function to provide a handle for the attachment of a lipophilic aliphatic group or for the attachment of a detectable moiety.
[0092] In one embodiment, one amino acid is an α-amino acid or a β-amino acid. One amino acid may be selected from the group consisting of Asp, β-Asp, β-Ser (3-amino-2-(hydroxymethyl)propanoic acid), β-homo-Ser (3-amino-4-hydroxybutyric acid), and β-Lys (3,6-diaminohexanoic acid).
[0093] As demonstrated by the inventors in Example 11, lipophilic aliphatic groups are essential to the present invention because they have a functional effect in vivo.
[0094] connectivity In one embodiment, the peptide and non-peptide portions of the PICK1 inhibitor of this disclosure are conjugated to form a PICK1 inhibitor having the general structure of formula (I).
[0095] [ka]
[0096] For example, if the lipophilic aliphatic group is described as a fatty acid, it is understood that only the carbonyl group of the carboxylic acid of the fatty acid is present in the PICK1 inhibitor. For example, when the fatty acid is conjugated to the linker amine, an amide bond is formed and water is lost at the same time. Thus, different components that are combined to form the PICK1 inhibitors of this disclosure may arise from the described compounds. In the particular case where the lipophilic aliphatic group is a diacid, in one embodiment, only one of the carboxylic acids reacts to form an amide with the linker amine, while the second carboxylic acid remains a carboxylic acid in the final PICK1 inhibitor.
[0097] The NPEG linker of this disclosure may, for example, contain a carboxylic acid at each end. The resulting NPEG linker observed in PICK1 inhibitors is understood to contain only the carbonyl group present in the amide bond formed when the NPEG linker is conjugated to the first and / or second peptide, but without the carboxylic acid. Thus, in one embodiment, the NPEG linker is conjugated to the first and / or second peptide via an amide bond formed between the carboxylic acid of the NPEG linker and the N-terminus of the first and / or second peptide. In one embodiment, the NPEG linker is conjugated to the first and / or second peptide via an amide bond formed between the carboxylic acid of the NPEG linker and the side-chain functional group of an amino acid in the first and / or second peptide, for example, by the formation of an amide bond between the carboxylic acid of the NPEG linker and the amine of the lysine side chain in the first and / or second peptide to form an amide.
[0098] The nitrogen atom of the NPEG linker may be further conjugated to a lipophilic aliphatic group, either directly or via a single amino acid. In one embodiment, the lipophilic aliphatic group is conjugated to the nitrogen atom of the NPEG linker via a functional group such as a carboxylic acid, for example, by forming an amide.
[0099] In one embodiment, a single amino acid is conjugated to the nitrogen atom of the NPEG linker via an α-carboxylic acid to form an amide, and further conjugated to a lipophilic aliphatic group. Further conjugation to a lipophilic aliphatic group may be via an α- or β-amine (an α- or β-amino acid, respectively) to form an amide bond, or via a side-chain functional group such as a carboxylic acid, alcohol, or amine to form an amide bond or ester bond.
[0100] Preferred structure In one embodiment, the PICK1 inhibitor is of formula (II)
[0101] [ka]
[0102] It has a structure that is During the ceremony, n is an integer between 0 and 12, preferably 2; p is an integer between 0 and 12, preferably 2.
[0103] In a preferred embodiment, the PICK1 inhibitor has the structure of formula (II), where n is 2 and p is 2. Such a structure is referred to herein as myr-NPEG4-(HWLKV)2.
[0104] Other preferred structures are disclosed below. Desaturation may be in a trans or cis configuration.
[0105] [ka]
[0106] [ka]
[0107] [ka]
[0108] [ka]
[0109] Mechanism of action As demonstrated in this disclosure and Example 3, it was surprisingly observed that the PICK1 inhibitor of the present invention can form a micelle structure. Compared to divalent peptide ligands that do not contain lipids and therefore cannot form a micelle structure, the improved efficacy of the PICK1 inhibitor of the present invention is presumed to be due to this micelle structure formation.
[0110] PICK1 is known to exist in a dimeric structure, and dimerization is mediated by the BAR domain. Dimerization of dimerized PICK1, which provides dimers of other dimers such as tetramers, has been reported to lead to autoinhibition of protein function (Karlsen, M. Let al. 2015). Therefore, it can be hypothesized that micelle PICK1 inhibitors can bind and aggregate several PICK1 proteins, thereby resulting in the observed effective inhibition of PICK1.
[0111] Therefore, in one embodiment, the PICK1 inhibitor self-assembles into a higher-order structure in solution, such as by self-assembling to form a micelle structure.
[0112] In one embodiment, the higher-order structure has a radius of gyration (Rg) of at least 15 Å, for example, at least 17 Å, for example, at least 19 Å, for example, at least 20 Å, for example, at least 21 Å, for example, at least 22 Å, for example, at least 23 Å.
[0113] In one embodiment, the higher-order structure has a radius of gyration (Rg) of at least 15 Å, for example, at least 17 Å, for example, at least 19 Å, for example, at least 20 Å, for example, at least 21 Å, for example, at least 22 Å, for example, at least 23 Å, for example, at least 24 Å, for example, at least 25 Å, for example, at least 26 Å, for example, at least 27 Å, for example, at least 28 Å, for example, at least 29 Å, for example, at least 30 Å, for example, at least 31 Å.
[0114] In one embodiment, the higher-order structure is formed from PICK1 inhibitors in the range of 4 to 20, for example, in the range of 4 to 18, for example, in the range of 4 to 16, for example, in the range of 4 to 14, for example, in the range of 4 to 12, for example, in the range of 4 to 10, for example, in the range of 4 to 8, for example, in the range of 6 to 8.
[0115] In one embodiment, the higher-order structure is formed from PICK1 inhibitors in the range of 4 to 40, for example, in the range of 6 to 40, for example, in the range of 8 to 40, for example, in the range of 10 to 40, for example, in the range of 12 to 40, for example, in the range of 14 to 40, for example, in the range of 16 to 40, for example, in the range of 18 to 40, for example, in the range of 20 to 40, for example, in the range of 22 to 40, for example, in the range of 24 to 40, for example, in the range of 26 to 40, for example, in the range of 28 to 40, for example, in the range of 30 to 40, for example, in the range of 32 to 40, for example, in the range of 34 to 40, for example, in the range of 36 to 40, for example, in the range of 38 to 40.
[0116] In one embodiment, the higher-order structure is formed from PICK1 inhibitors in the range of 4 to 40, for example, in the range of 4 to 38, for example, in the range of 4 to 36, for example, in the range of 4 to 34, for example, in the range of 4 to 32, for example, in the range of 4 to 30, for example, in the range of 4 to 28, for example, in the range of 4 to 26, for example, in the range of 4 to 24, for example, in the range of 4 to 22, for example, in the range of 4 to 20, for example, in the range of 4 to 18, for example, in the range of 4 to 16, for example, in the range of 4 to 14, for example, in the range of 4 to 12, for example, in the range of 4 to 10, for example, in the range of 4 to 8, for example, in the range of 4 to 6.
[0117] In one embodiment, the higher-order structure is formed from 4 to 40 PICK1 inhibitors, for example, in the range of 6 to 38, for example, in the range of 6 to 36, for example, in the range of 8 to 34, for example, in the range of 8 to 32, for example, in the range of 10 to 30, for example, in the range of 10 to 28, for example, in the range of 12 to 26, for example, in the range of 14 to 24, for example, in the range of 16 to 24, for example, in the range of 16 to 22, for example, in the range of 18 to 22, for example, in the range of 19 to 21, for example, in the range of 20 PICK1 inhibitors.
[0118] In one embodiment, micelles containing a PICK1 inhibitor as disclosed herein are provided.
[0119] In one embodiment, a) A first peptide containing the amino acid sequence of general formula: X1X2X3X4X5; and b) A second peptide containing the amino acid sequence X1X2X3X4X5; (In the formula: X1 is either H, N, F, or T, or does not exist; X2 is W, S, E, or Y; or it does not exist; X3 is L, V, or I; X4 is K, I, or R; and X5 is V. c) A linker that links the first peptide to the second peptide, and d) Lipophilic aliphatic group A micelle containing a PICK1 inhibitor is provided.
[0120] As described herein, the PICK1 inhibitors of this disclosure can bind to the PDZ domain of PICK1.
[0121] In the natural PICK1 dimer structure, the distance between the PDZ domains of the PICK1 dimer is estimated to be approximately 180 Å. In a PICK1 inhibitor containing an NPEG linker having the length of four ethylene glycol moieties, the distance between the first and second peptides is estimated to be in the range of approximately 43 Å. Therefore, such a PICK1 inhibitor cannot bind the two PDZ domains found in a single PICK1 dimer. This supports the assumption that a single PICK1 inhibitor, such as those disclosed herein, functions by binding and combining two PICK1 dimers, thereby resulting in PICK1 inhibition. Thus, micelle structures formed by several PICK1 inhibitors, such as those disclosed herein, may be able to bind and combine two or more PICK1 dimers, thereby resulting in effective PICK1 inhibition as disclosed herein.
[0122] Accordingly, in one embodiment, a PICK1 inhibitor or micelle structure as disclosed herein binds to the PDZ domains of two or more PICK1 proteins, resulting in inhibition of PICK1. In one embodiment, the two or more PICK1 proteins bound by the PICK1 inhibitor of this disclosure are present in two or more dimers of PICK1.
[0123] In one embodiment, binding of a PICK1 inhibitor to PICK1 results in the formation of higher-order oligomeric states of PICK1, such as trimers, tetramers, pentamers, hexamers, heptamers, or octamers. In one embodiment, binding of a PICK1 inhibitor to PICK1 results in the formation of tetramers, hexamers, or octamers of PICK1.
[0124] In one embodiment, the PICK1 inhibitor of the present disclosure aggregates two or more PICK1 proteins. In one embodiment, the compound aggregates four PICK1 proteins, for example five PICK1 proteins, for example six PICK1 proteins, for example seven PICK1 proteins, for example eight PICK1 proteins, for example nine PICK1 proteins, for example ten PICK1 proteins.
[0125] Inhibition of PICK1 by binding to the PICK1 inhibitor of this disclosure may prevent the PICK1 protein from interacting with AMPAR, thereby preventing PICK1 from regulating AMPAR traffic. Thus, in one embodiment, a PICK1 inhibitor can inhibit the protein-protein interaction between PICK1 and AMPAR. This may therefore prevent PICK1 from downregulating GluA2 and prevent CP-AMPAR formation, thereby preventing maladaptive plasticity in response to abnormal levels of glutamate at the synapse. This, in turn, may prevent, for example, neuropathic pain and cocaine addiction.
[0126] The PICK1 inhibitors of this disclosure maintain high affinity for the PDZ domain of PICK1. In one embodiment, the PICK1 inhibitors of this disclosure have a PICK1 Ki of less than 10 nM, e.g., less than 9 nM, e.g., less than 8 nM, e.g., less than 7 nM, e.g., less than 6 nM, e.g., less than 5 nM, e.g., less than 4 nM, e.g., less than 3 nM, e.g., less than 2 nM, e.g., less than 1 nM, e.g., less than 0.5 nM.
[0127] The affinity of the PICK1 inhibitors of this disclosure for the PDZ domain of PICK1 can be measured by fluorescence polarization (FP) as described in Example 4 of this specification.
[0128] The ability of the PICK1 inhibitors of this disclosure to form higher-order structures can be measured by size exclusion chromatography (SEC) or small-angle X-ray scattering (SAXS), as described herein, in Example 3.
[0129] Detectable portion In one embodiment, the PICK1 inhibitor of the present disclosure further includes a detectable moiety. Conventional moieties known to those skilled in the art for the detection of fluorophores, chromophores, radioisotopes, or enzymes can be used. The presence of a detectable moiety in the PICK1 inhibitor enables the labeling and visualization of PICK1 upon binding to the PICK1 inhibitor.
[0130] In one embodiment, the detectable portion is conjugated to a first and / or second peptide. In another embodiment, the detectable portion is conjugated to a single amino acid of the non-peptide portion.
[0131] In one embodiment, the detectable portion is a fluorophore such as 5,6-carboxytetramethylrhodamine (TAMRA) or indodicarbocyanine (Cy5).
[0132] In another embodiment, the detectable portion contains or consists of a radioactive isotope. The radioactive isotope is 125 I, 99m Tc, 111 In, 67Ga, 68 Ga, 72 As, 89 Zr, 123 I, 18 F and 201 You may select from the group consisting of Tl.
[0133] Diseases and Disabilities The present invention provides pharmaceutical compositions for the treatment of diseases and / or disorders associated with maladaptive plasticity. In one embodiment, a pharmaceutical composition comprising a PICK1 inhibitor as disclosed herein or micelles as described herein is provided. The pharmaceutical composition may comprise the PICK1 inhibitor or micelles of the present disclosure in a pharmaceutically acceptable carrier.
[0134] AMPA-type glutamate receptors (AMPARs), in contrast to NMDA-type glutamate receptors (NMDARs), typically have a monovalent cation (i.e., Na) due to the presence of the GluA2 subunit in the tetrameric receptor complex. + and K + It is permeable only to ). Changes in plasticity in response to strong and sustained depolarization, however, increase conductance and Ca in some synaptic types. 2+ This leads to a switch to permeable (CP-AMPAR) AMPAR, and this switch makes the synapse hypersensitive. Mechanically, CP-AMPAR expression involves the initial PICK1-dependent downregulation of GluA2 containing AMPAR, mediated by the interaction between the PICK1 PDZ domain and the C-terminus of the GluA2 subunit of AMPAR. This, in turn, allows for the insertion of a GluA2-deficient receptor in the synapse (slot hypothesis), and synaptic Ca 2+ To make it permeable and hypersensitive.
[0135] CP-AMPAR is critically involved in cocaine craving after self-administration and detoxification in rats (Conrad et al 2008). PICK1 is involved in the expression of CP-AMPAR in VTA dopaminergic neurons in the midbrain and in the nucleus accumbens during the development of cocaine craving (Luscher et al 2011 and Wolf et al 2010), suggesting PICK1 as a target in cocaine addiction. CPP-conjugated divalent peptide inhibitors of PICK1 have been reported to dose-dependently attenuate the recovery of cocaine craving in rats (Turner et al. 2020). Therefore, in one embodiment, administration of the PICK1 inhibitor of this disclosure reduces cocaine craving in drug addictions such as cocaine addiction.
[0136] Upregulation of AMPA-type glutamate receptors (AMPARs) in spinal dorsal horn (DH) neurons leads to central sensitization, a specific form of synaptic plasticity in the DH that persists over time (Woolf et al 2000 and Ji et al 2003). Furthermore, both peripheral inflammatory pain and nerve injury-induced pain are associated with Ca 2+It causes upregulation of permeable AMPARs (CP-AMPARs) (Vikman et al 2008, Gangadharan et al 2011, and Chen et al 2013). Early evidence for the role of PICK1 in neuropathic pain came from Garry et al 2003, which showed that peptide inhibitors of PICK1 alleviated pain induced by chronic stenotic injury (CCI). Thus, shRNA-mediated knockdown of PICK1 has been shown to reduce complete Freund's adjuvant (CFA)-induced inflammatory pain, and PICK1 knockout mice were found to completely fail to develop pain in response to spinal nerve ligation (SNL) (Wang et al 2011 and Atianjoh et al 2010). Indeed, administration of the PICK1 inhibitors of this disclosure reduces mechanical allodynia (SNI model - Example 8), inflammatory pain (CFA model - Examples 7 and 16), and thermal allodynia (CFA model - Example 17) in models of neuropathic pain. Thus, in one embodiment, the pain is mechanical or thermal allodynia or hyperalgesia. In another embodiment, the pain is inflammatory pain.
[0137] Both TAR DNA-binding protein 43 (TDP-43) pathology and failure of RAN editing of the AMPA receptor subunit GluA2 are pathogenesis-related molecular abnormalities that occur simultaneously in the majority of motor neurons in patients with amyotrophic lateral sclerosis (ALS). Pain symptoms in a mouse model with conditional knockout of the RNA editing enzyme adenosine deaminase, which acts on RNA2 (ADAR2), were alleviated by perampanel, an AMPA antagonist, suggesting the potential for symptom relief with the PICK1 inhibitors of this disclosure.
[0138] Considering the effects of the compounds disclosed herein on pain and poisoning, it is reasonable to expect good efficacy in patients with comorbidities, such as pain patients who also suffer from poisoning.
[0139] Similar central sensitization is thought to be underpinned by allodynia in hyperalgesic priming, which serves as an experimental model for low back pain and migraines (Kandasamy et al 2015).
[0140] Similarly, the etiology of tinnitus shares some similarities with neuropathic pain, including central sensitization (Vanneste et al 2019, Peker et al 2016, and Moller et al 2007).
[0141] The role of PICK1 in surface stabilization / insertion of CP-AMPARs has been explained in relation to oxygen-glucose depletion in cultured hippocampal neurons (Clem et al 2010 and Dixon et al 2009). This induces PICK1 as a putative target in protecting neuronal cell death after ischemic injury.
[0142] Loss of PICK1 has been shown to protect neurons in vitro and in vivo against amyloid-beta-responsive spinal loss (Marcotte et al 2018 and Alfonso et al 2014). As a result, PICK1 is a putative target for symptomatic and possibly prophylactic treatment of Alzheimer's disease.
[0143] PICK1 interacts with and inhibits parkin, an E3 ubiquitin ligase involved in mitophagy. Loss of parkin function is associated with both sporadic and familial Parkinson's disease (PD). As a result, PICK1 knockout mice are resistant to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated toxicity (He et al 2018). Consequently, PICK1 is a putative target for symptomatic and possibly prophylactic treatment of Parkinson's disease.
[0144] Overstimulation of glutamate receptors, leading to excessive intracellular calcium concentrations, is a major cause of neuronal cell death in epilepsy. The GluR2 (GluA2) hypothesis suggests that following neurological injury such as epileptic seizures, the AMPA receptor subunit GluR2 protein is downregulated. This increases the likelihood of the formation of calcium-permeable AMPA receptors with GluR2 deletion, which may further enhance the toxicity of the neurotransmitter glutamate (Lorgen et al 2017).
[0145] PICK1 is overexpressed in tumor cells compared to adjacent normal epithelium in breast, lung, gastric, colorectal, and ovarian cancers. High levels of PICK1 expression correlate with a shortened overall survival, as determined by immunostaining of breast cancer tissue microarrays. Therefore, transfection of MDA-MB-231 cells with PICK1 siRNA reduced cell proliferation and colonization in vitro and inhibited oncogenicity in nude mice (Zhang et al 2010). Thus, PICK1 is a putative target for cancer treatment and prognostic indicators.
[0146] In one embodiment, a PICK1 inhibitor, micelle, or pharmaceutical composition as disclosed herein is provided for use as a pharmaceutical.
[0147] In one embodiment, a PICK1 inhibitor, micelle, or pharmaceutical composition as disclosed herein is provided for use in the prevention and / or treatment of diseases or disorders associated with maladaptive plasticity.
[0148] In one embodiment, a method is provided for the prevention and / or treatment of a disease or disorder related to maladaptive plasticity in a subject, the method comprising administering a PICK1 inhibitor, micelle or pharmaceutical composition of the present disclosure to a subject.
[0149] In one embodiment, the use of the PICK1 inhibitor, micelle, or pharmaceutical composition of the present disclosure is provided for the manufacture of pharmaceuticals for the treatment of diseases and / or disorders associated with maladaptive plasticity.
[0150] In one embodiment, diseases or disorders associated with maladaptive plasticity include pain, drug addiction, amyotrophic lateral sclerosis, epilepsy, tinnitus, migraine, cancer, ischemia, Alzheimer's disease, and / or Parkinson's disease.
[0151] In one embodiment, the disease or disorder associated with maladaptive plasticity is pain, such as neuropathic pain. The pain may be inflammatory pain or neuropathic pain. The pain being treated may be chronic pain, which may be chronic neuropathic pain or chronic inflammatory pain. Neuropathic pain may be induced by damage to the peripheral or central nervous system as a result of traumatic injury, surgery, or a disease such as diabetes or autoimmune disease. Neuropathic pain may be induced by treatment using chemotherapy. If the pain persists, the condition is chronic neuropathic pain. Chronic inflammatory pain may be induced by inflammation after nerve injury, and may also be initiated by inflammation induced by foreign bodies in which mediators released by immune cells cause sensitization of the pain pathway, i.e., "wind-up" of sensory neurons located in the spinal cord. Therefore, an effective analgesic needs to find its target, in this case PICK1, so that it can reach spinal cord tissue and have a pain-relieving effect. Thus, the compound needs to be able to cross the blood-brain barrier and / or blood-spinal cord barrier so that it can reach spinal cord tissue.
[0152] In one embodiment, the disease or disorder associated with maladaptive plasticity is a drug addiction, such as cocaine addiction, opioid addiction, or morphine addiction.
[0153] In one embodiment, the disease or disorder associated with maladaptive plasticity is a cancer such as breast cancer, e.g., histological grade, lymph node metastasis, Her-2 / neu positive, and triple-negative basement membrane cell-like breast cancer.
[0154] In one embodiment, the disease or disorder associated with maladaptive plasticity is amyotrophic lateral sclerosis (ALS).
[0155] In one embodiment, the disease or disorder associated with maladaptive plasticity is epilepsy.
[0156] In one embodiment, the disease or disorder associated with maladaptive plasticity is tinnitus.
[0157] In one embodiment, the disease or disorder associated with maladaptive plasticity is migraine.
[0158] In one embodiment, the disease or disorder associated with maladaptive plasticity is stroke or ischemia.
[0159] In one embodiment, the disease or disorder associated with maladaptive plasticity is Alzheimer's disease.
[0160] In one embodiment, the disease or disorder associated with maladaptive plasticity is Parkinson's disease.
[0161] In yet another embodiment, compounds such as those disclosed herein are for use in the prevention and / or treatment of head injuries.
[0162] In yet another embodiment, compounds such as those disclosed herein are for use in the prevention and / or treatment and / or diagnosis of cancers such as breast cancer.
[0163] Subjects who are at risk of or currently suffer from the above-mentioned disabilities and diseases may be given either preventive measures to reduce the risk of developing the disability or disease, or therapeutic measures after the onset of the disability or disease. Subjects may be mammals or human patients.
[0164] Administration Conventional methods known to those skilled in the art of medicine can be used to administer the PICK1 inhibitors of this disclosure to patients. The PICK1 inhibitors of this disclosure can be administered alone or in combination with other therapeutic agents or interventions.
[0165] In one embodiment, the PICK1 inhibitor of the Disclosure is administered by parenteral administration, such as intravenous, intraperitoneal, intramuscular, intrathecal, transdermal, transmucosal, or subcutaneous administration. In one embodiment, the PICK1 inhibitor of the Disclosure is administered by intracavitary or subcutaneous administration. In a preferred embodiment, the PICK1 inhibitor of the Disclosure is administered by subcutaneous administration. As shown in Example 15, the PICK1 inhibitor of the Disclosure maintains high solubility, making it suitable for such subcutaneous administration at an effective dose.
[0166] diagnosis The PICK1 inhibitors of this disclosure may include a detectable portion. Such PICK1 inhibitors can therefore be used for diagnostic purposes, such as by detecting PICK1 in a tissue or sample.
[0167] Accordingly, this disclosure provides PICK1 inhibitors, as disclosed herein, for use in the diagnosis of diseases or disorders related to maladaptive plasticity.
[0168] PICK1 is overexpressed in tumor cells compared to adjacent normal epithelium in breast, lung, gastric, colorectal, and ovarian cancers. High levels of PICK1 expression correlate with a shortened overall survival, as determined by immunostaining of breast cancer tissue microarrays. Therefore, transfection of MDA-MB-231 cells with PICK1 siRNA reduced cell proliferation and colonization in vitro and inhibited oncogenicity in nude mice (Zhang et al 2010). Thus, PICK1 is a putative target for cancer treatment and prognostic indicators.
[0169] In one embodiment, PICK1 inhibitors as disclosed herein are for use in the diagnosis of maladaptive plasticity-related diseases or disorders, such as breast cancer. In one embodiment, breast cancer is selected from histological grade, lymph node metastasis, Her-2 / neu-positive, and triple-negative basement membrane cell-like breast cancer.
[0170] This disclosure further provides a method for diagnosing breast cancer in subjects who require it, and the method is: a. Step of obtaining a tissue sample from the above subject; b. A step of staining a sample with a compound such as those disclosed herein; c. A step of measuring the level of PICK1 in the sample; and d. Step of comparing the level of PICK1 in the sample with a healthy standard. Includes, An increase in PICK1 levels in the sample suggests that the individual in question has breast cancer.
[0171] This disclosure further provides a method for predicting the prognosis of subjects with breast cancer, and the method is: a. Step of obtaining a tissue sample from the above subject; b. A step of staining a sample with a compound such as those disclosed herein; c. A step of measuring the level of PICK1 in the sample; and d. Step of comparing the level of PICK1 in the sample with a healthy standard. Includes, An increase in PICK1 levels in the sample suggests a poor prognosis.
[0172] In one embodiment, a PICK1 inhibitor as disclosed herein is used to stratify subjects suffering from maladaptive plasticity-related diseases into responders and non-responders to treatment with the PICK1 inhibitor. Such stratification can be used to evaluate the efficacy of PICK1 inhibitors having divalent or polyvalent interactions with PICK1 before initiating other treatment methods, such as AAV-based therapies, which result in similar mechanisms of treatment, such as PICK1 inhibition. The advantage of such stratification is that only responders to treatment mechanisms such as PICK1 inhibition receive long-term, irreversible treatment with AAV-based therapies. AAV-based therapies are described in concurrently pending applications (PCT / EP2019 / 078736 and EP20161524.2).
[0173] Therefore, in one embodiment, the PICK1 inhibitor of the present disclosure is used to stratify patients with diseases and / or disorders associated with maladaptive plasticity into predictable treatment responders to gene therapy.
[0174] In one embodiment, the PICK1 inhibitor of the present disclosure is used to stratify subjects suffering from maladaptive plasticity-related diseases into responders and non-responders to treatment with the compound.
[0175] Clause 1. A PICK1 inhibitor comprising a peptide portion and a non-peptide portion, wherein the peptide portion is a) A first peptide containing the amino acid sequence of general formula: XX2X3X4X5; and b) A second peptide containing the amino acid sequence X1X2X3X4X5 in general formula. (In the formula, X1 is either H, N, F, or T, or does not exist; X2 is W, S, E, or Y; or it does not exist; X3 is L, V, or I; X4 is K, I, or R; and X5 is V. Composed of; The non-peptide portion is: c) A linker that links the first peptide to the second peptide, and d) Lipophilic aliphatic group PICK1 inhibitors, including those mentioned above.
[0176] 2. A PICK1 inhibitor as described in any one of the above clauses, wherein the first and / or second peptide is selected from the group consisting of HWLKV, FEIRV, NSIIV, NSVRV, NSLRV, NSIRV, NYIIV, NYIRV, TSIRV, YIIV, SVRV, EIRV, LRV, IIV, VRV, and IRV.
[0177] 3. A PICK1 inhibitor as described in any one of the above clauses, wherein the first and / or second peptide is selected from the group consisting of HWLKV, NSVRV, NSLRV, NSIRV, TSIRV, EIRV, YIIV, IIV, VRV, and IRV.
[0178] 4. A PICK1 inhibitor as described in any one of the above clauses, wherein the first and / or second peptide is selected from the group consisting of NSVRV, NSLRV, NSIRV, TSIRV, EIRV, YIIV, IIV, VRV, and IRV.
[0179] 5. A PICK1 inhibitor as described in any one of the above clauses, wherein the first and / or second peptide is selected from the group consisting of HWLKV, FEIRV, NSIIV, NSVRV, NSLRV, NSIRV, YIIV, SVRV, VRV, and LRV.
[0180] 6. A PICK1 inhibitor as described in any one of the above clauses, wherein the first and / or second peptide is selected from the group consisting of FEIRV, NSIIV, NSVRV, NSLRV, NSIRV, YIIV, SVRV, VRV, and LRV.
[0181] 7. A PICK1 inhibitor as described in any one of the above clauses, wherein the first and / or second peptide is HWLKV.
[0182] 8. X1 is N, F, or T, or does not exist; X2 is S, E, or Y; or it does not exist; X3 is V, L, or I; X4 is either I or R; and X5 is V. A PICK1 inhibitor as described in Clause 1.
[0183] 9. X1 is either N or T, or does not exist; X2 is S, E, or Y; or it does not exist; X3 is V, L, or I; X4 is either I or R; and X5 is V. A PICK1 inhibitor as described in Clause 1.
[0184] 10. X1 is either N or F, or does not exist; X2 is S, E, or Y; or it does not exist; X3 is V, L, or I; X4 is either I or R; and X5 is V. A PICK1 inhibitor as described in Clause 1.
[0185] 11. A PICK1 inhibitor as described in any one of the above clauses, wherein the first peptide is identical to the second peptide.
[0186] 12. A PICK1 inhibitor as described in any one of the above clauses, wherein the linker is an NPEG linker.
[0187] 13. The PICK1 inhibitor according to any one of the above clauses, wherein the NPEG linker comprises 0 to 24 ethylene glycol moieties in the range of 0 to 20, for example, 0 to 16, for example, 0 to 14, for example, 0 to 12, for example, 0 to 10, for example, 0 to 8, for example, 0 to 6, for example, 0 to 4, for example, 0 to 2 ethylene glycol moieties in the range of 0 to 2, wherein one or more backbone oxygen atoms are replaced by nitrogen atoms, and preferably the NPEG linker comprises 4 ethylene glycol moieties in which one or more backbone oxygen atoms are replaced by nitrogen.
[0188] 14. A PICK1 inhibitor as described in any one of the above clauses, wherein one of the skeletal oxygen atoms of the NPEG-linker is replaced with a nitrogen atom.
[0189] 15. A PICK1 inhibitor according to any one of the above clauses, wherein the NPEG linker comprises a carboxylic acid at each end.
[0190] 16. The PICK1 inhibitor described in any one of the above clauses, wherein one or more nitrogen atoms of the NPEG linker are located at any position along the NPEG linker, such as, for example, located in the center of the NPEG linker or located toward one end of the NPEG linker.
[0191] 17. A PICK1 inhibitor according to any one of the above clauses, wherein the NPEG linker is conjugated to the first and / or second peptide via an amide bond formed between the carboxylic acid of the NPEG linker and the N-terminus of the first and / or second peptide.
[0192] 18. A PICK1 inhibitor according to any one of the above clauses, wherein the lipophilic aliphatic group is an aliphatic chain or an aliphatic ring.
[0193] 19. A PICK1 inhibitor according to any one of the above clauses, wherein the lipophilic aliphatic group is an aliphatic branched or unbranched chain.
[0194] 20. The PICK1 inhibitor according to any one of the preceding clauses, wherein the lipophilic aliphatic group is an aliphatic saturated or unsaturated chain.
[0195] 21. The PICK1 inhibitor according to any one of the preceding clauses, wherein the lipophilic aliphatic group is an aliphatic ring comprising a gonane structure such as sterol.
[0196] 22. The PICK1 inhibitor according to any one of the preceding clauses, wherein the lipophilic aliphatic group is an aliphatic ring comprising a steroid such as cholesterol.
[0197] 23. The PICK1 inhibitor according to any one of the preceding clauses, wherein the lipophilic aliphatic group further comprises a functional group such as carboxylic acid, alcohol or amine.
[0198] 24. The PICK1 inhibitor according to any one of the preceding clauses, wherein the lipophilic aliphatic group comprises an alcohol.
[0199] 25. The PICK1 inhibitor according to any one of the preceding clauses, wherein the lipophilic aliphatic group comprises a carboxylic acid.
[0200] 26. The PICK1 inhibitor according to any one of the preceding clauses, wherein the lipophilic aliphatic group is a fatty acid.
[0201] 27. The lipophilic aliphatic group is C4~C 26 The PICK1 inhibitor according to any one of the preceding clauses, which is a fatty acid.
[0202] 28. The PICK1 inhibitor according to any one of the preceding clauses, wherein the lipophilic aliphatic group is a saturated fatty acid or an unsaturated fatty acid.
[0203] 29. A PICK1 inhibitor according to any one of the above clauses, wherein the lipophilic aliphatic group is selected from the group consisting of acetic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, margaric acid, stearic acid, arachidonic acid, behenic acid, lignoceric acid, cerotic acid, caproleic acid, lauroleic acid, myristoleic acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, gadoleic acid, and erucic acid.
[0204] 30. A PICK1 inhibitor according to any one of the above clauses, wherein the lipophilic aliphatic group is selected from the group consisting of capric acid, lauric acid, myristic acid, palmitic acid, margaric acid, and stearic acid.
[0205] 31. A PICK1 inhibitor according to any one of the above clauses, wherein the lipophilic aliphatic group is myristic acid.
[0206] 32. A PICK1 inhibitor according to any one of the above clauses, wherein the lipophilic aliphatic group is a diacid, such as tetradecanediic acid, hexadecanedioic acid, or octadecanediic acid.
[0207] 33. A PICK1 inhibitor according to any one of the above clauses, wherein a lipophilic aliphatic group is conjugated to the nitrogen atom of the NPEG linker via a functional group such as a carboxylic acid, for example by forming an amide.
[0208] 34. A PICK1 inhibitor according to any one of the above clauses, wherein the non-peptide portion further comprises one amino acid.
[0209] 35. A PICK1 inhibitor according to any one of clauses 14-15, wherein one amino acid is either an α-amino acid or a β-amino acid.
[0210] 36. A PICK1 inhibitor according to any one of clauses 14 to 16, wherein one amino acid is selected from the group consisting of Asp, β-Asp, β-Ser, β-homo-Ser, and β-Lys.
[0211] 37. The PICK1 inhibitor according to clause 14, wherein one amino acid is conjugated to the nitrogen atom of the NPEG linker via an α-carboxylic acid to form an amide, and is further conjugated to a lipophilic aliphatic group.
[0212] 38. The PICK1 inhibitor according to any one of clauses 14 to 17, wherein one amino acid is conjugated to a lipophilic aliphatic group via an α- or β-amine to form an amide bond, or via a side chain functional group such as a carboxylic acid, alcohol or amine to form an amide bond or an ester bond.
[0213] 39. Formula (I):
[0214]
Chemical formula
[0215] has the general structure of, wherein, Z is a single bond or a single amino acid; n is an integer of 0 to 12; p is an integer of 0 to 12, The PICK1 inhibitor according to any one of the preceding clauses.
[0216] 40. Formula (II):
[0217]
Chemical formula
[0218] has the structure according to, wherein, n is an integer of 0 to 12, preferably 2; p is an integer of 0 to 12, preferably 2, The PICK1 inhibitor according to any one of the preceding clauses.
[0219] 41. A PICK1 inhibitor described in any one of the above clauses, which self-assembles into a higher-order structure in solution, such as by self-assembling to form a micelle structure.
[0220] 42. The higher-order structure has a radius of gyration (R) of at least 15 Å, e.g., at least 17 Å, e.g., at least 19 Å, e.g., at least 20 Å, e.g., at least 21 Å, e.g., at least 22 Å, e.g., at least 23 Å, e.g., at least 24 Å, e.g., at least 25 Å, e.g., at least 26 Å, e.g., at least 27 Å, e.g., at least 28 Å, e.g., at least 29 Å, e.g., at least 30 Å, e.g., at least 31 Å. g A PICK1 inhibitor according to any one of clauses 20 to 21, having the following characteristics:
[0221] 43. A PICK1 inhibitor described in any one of the above clauses, which binds to the PDZ domain of PICK1.
[0222] 44. A PICK1 inhibitor according to any one of the above clauses, which binds to the PDZ domains of two or more PICK1 proteins.
[0223] 45. A PICK1 inhibitor as described in any one of the above clauses, which can inhibit the protein-protein interaction between PICK1 and AMPAR.
[0224] 46. A PICK1 inhibitor that can inhibit PICK1, as described in any one of the above clauses.
[0225] 47. A PICK1 inhibitor according to any one of the above clauses, wherein the peptide has a PICK1 Ki of less than 10 nM, e.g. less than 9 nM, e.g. less than 8 nM, e.g. less than 7 nM, e.g. less than 6 nM, e.g. less than 5 nM, e.g. less than 4 nM, e.g. less than 3 nM, e.g. less than 2 nM, e.g. less than 1 nM, e.g. less than 0.5 nM.
[0226] 48. A PICK1 inhibitor as described in any one of the above clauses, wherein the binding of the PICK1 inhibitor to PICK1 results in the formation of a higher-order oligomeric state of PICK1, such as a trimer, tetramer, pentamer, hexamer, heptamer, or octamer of PICK1.
[0227] 49. A PICK1 inhibitor as described in any one of the above clauses, wherein the binding of the PICK1 inhibitor to PICK1 results in the formation of a tetramer, hexamer, or octamer of PICK1.
[0228] 50. A PICK1 inhibitor as described in any one of the above clauses, further including a detectable portion.
[0229] 51. A PICK1 inhibitor according to any one of the above clauses, wherein the detectable portion is conjugated to a first and / or second peptide.
[0230] 52. A PICK1 inhibitor according to any one of the above clauses, wherein the detectable portion is conjugated to one amino acid of the non-peptide portion.
[0231] 53. A PICK1 inhibitor according to Clause 27, wherein the detectable portion is a fluorophore, chromophore, or enzyme.
[0232] 54. A PICK1 inhibitor according to Clause 27, wherein the detectable portion is 5,6-carboxytetramethylrhodamine (TAMRA) or indodicarbocyanine (Cy5).
[0233] 55. A PICK1 inhibitor as described in Clause 27, wherein the detectable portion contains or consists of a radioactive isotope.
[0234] 56. Radioactive isotopes, 125 I, 99m Tc, 111 In, 67 Ga, 68 Ga, 72 As, 89 Zr, 123 I, 18 F and 201A PICK1 inhibitor as described in Clause 30, selected from the group consisting of Tl.
[0235] 57. A micelle containing the PICK1 inhibitor described in any one of the above clauses.
[0236] 58. A pharmaceutical composition comprising a PICK1 inhibitor as described in any one of Clauses 1 to 56 or a micelle as described in Clause 57.
[0237] 59. PICK1 inhibitors, micelles, or pharmaceutical compositions as described in any one of the above clauses, for use as pharmaceuticals.
[0238] 60. PICK1 inhibitors, micelles, or pharmaceutical compositions as described in any one of the above clauses, for use in the prevention and / or treatment of diseases or disorders related to maladaptive plasticity.
[0239] 61. A method for providing prevention and / or treatment of a disease or disorder related to maladaptive plasticity in a subject, comprising administering to the subject a PICK1 inhibitor, micelle or pharmaceutical composition as described in any one of the above clauses.
[0240] 62. Use of PICK1 inhibitors, micelles, or pharmaceutical compositions described in any one of the above clauses for the manufacture of pharmaceuticals for the treatment of diseases and / or disorders related to maladaptive plasticity.
[0241] 63. PICK1 inhibitors, micelles, or pharmaceutical compositions for use as described in any one of Clauses 59-60, for use as described in Clause 61 or Clause 62, for use as described in Clause 61, for use as described in Clause 62, for use as described in any one of Clauses 59-60, for use as described in Clause 61, for use as described in Clause 62, for use as described in Clause 61, for use as described in Clause 62, for use as described in any one of Clauses 59-60, for use as described in any one of Clauses 61, for use as described in any one of Clauses 61, for use as described in any one of Clauses 62, for use as described in any one of Clauses 61
[0242] 64. A PICK1 inhibitor, micelle or pharmaceutical composition for use as described in any one of Clauses 59-60, for use as described in Clause 61 or Clause 62, for a disease or disorder related to maladaptive plasticity, which is pain such as inflammatory pain or neuropathic pain.
[0243] 65. A PICK1 inhibitor, micelle, or pharmaceutical composition for use as described in Clause 64, wherein the pain is mechanical or thermal allodynia or hyperalgesia.
[0244] 66. PICK1 inhibitors, micelles, or pharmaceutical compositions for use as described in any one of Clauses 59-60, for use as described in Clause 61 or Clause 62, for use as described in Clause 61, for use as described in Clause 62, for use as described in any one of Clauses 59-60, for use as described in Clause 61, for use as described in Clause 62, for use as described in Clause 61, for use as described in Clause 62, for use as described in any one of Clauses 59-60, for use as described in any one of Clauses 61
[0245] 67. If the disease or disorder associated with maladaptive plasticity is a cancer such as breast cancer, for example, histological grade, lymph node metastasis, Her-2 / neu positive, and triple-negative basement membrane cell-like breast cancer, then PICK1 inhibitors, micelles, or pharmaceutical compositions for use as described in any one of Clauses 59-60, the method described in Clause 61, or the use described in Clause 62.
[0246] 68. PICK1 inhibitors, micelles, or pharmaceutical compositions for use as described in any one of Clauses 59-60, for use as described in Clause 61 or Clause 62, for use in which the disease or disorder associated with maladaptive plasticity is amyotrophic lateral sclerosis.
[0247] 69. A PICK1 inhibitor, micelle or pharmaceutical composition for use as described in any one of Clauses 59-60, the method described in Clause 61 or the use described in Clause 62, if the disease or disorder associated with maladaptive plasticity is epilepsy.
[0248] 70. A PICK1 inhibitor, micelle or pharmaceutical composition for use as described in any one of Clauses 59-60, if the disease or disorder associated with maladaptive plasticity is tinnitus, the method described in Clause 61 or the use described in Clause 62.
[0249] 71. A PICK1 inhibitor, micelle or pharmaceutical composition for use as described in any one of Clauses 59-60, if the disease or disorder associated with maladaptive plasticity is migraine, the method described in Clause 61 or the use described in Clause 62.
[0250] 72. A PICK1 inhibitor, micelle or pharmaceutical composition for use as described in any one of Clauses 59-60, for use as described in Clause 61 or Clause 62, for a disease or disorder related to maladaptive plasticity, which is ischemia.
[0251] 73. PICK1 inhibitors, micelles, or pharmaceutical compositions for use as described in any one of Clauses 59-60, the method described in Clause 61, or the use described in Clause 62, for use in which the disease or disorder associated with maladaptive plasticity is Alzheimer's disease.
[0252] 74. PICK1 inhibitors, micelles, or pharmaceutical compositions for use as described in any one of Clauses 59-60, the method described in Clause 61, or the use described in Clause 62, for use in which the disease or disorder associated with maladaptive plasticity is Parkinson's disease.
[0253] 75. PICK1 inhibitors as described in any one of Clauses 1 to 56 or micelles as described in Clause 57, for use in the diagnosis of diseases or disorders related to maladaptive plasticity.
[0254] 76. PICK1 inhibitors for use in the diagnosis described in Clause 75, where the disease or disorder associated with maladaptive plasticity is cancer, such as breast cancer.
[0255] 77. PICK1 inhibitors for use as described in Clause 76, selected from breast cancers of histological grade, lymph node metastasis, Her-2 / neu positive, and triple-negative basement membrane cell-like breast cancer.
[0256] 78. A method for diagnosing breast cancer in a subject for which it is necessary, a. Step of obtaining tissue samples from the above subjects; b. The step of staining the sample with a PICK1 inhibitor as described in any one of clauses 50 to 56; c. A step of measuring the level of PICK1 in the sample; and d. Step of comparing the level of PICK1 in the sample with a healthy standard. Includes, A method by which an increase in the level of PICK1 in the sample suggests that the individual has breast cancer.
[0257] 79. A method for predicting the prognosis of a subject who has breast cancer, a. Step of obtaining tissue samples from the above subjects; b. The step of staining the sample with a PICK1 inhibitor as described in any one of clauses 50 to 56; c. A step of measuring the level of PICK1 in the sample; and d. Step of comparing the level of PICK1 in the sample with a healthy standard. Includes, A method in which an increase in the level of PICK1 in the sample suggests a poor prognosis.
[0258] Examples Example 1: PICK1 expression and purification Full-length rat PICK1 (pET41) was prepared as previously described (Madsen et al., 2005). In short, PICK1 was expressed in BL21-DE3-pLysS cells and grown at 37°C. 600The cells were induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at a pH of 0.6 and grown at 20°C for 16 hours. The cultures were harvested and resuspended per 1 L of culture in a cOmplete protease inhibitor cocktail (Roche) consisting of 50 mM tris-aminomethane (Tris), 125 mM NaCl, 2 mM dithiothreitol (DTT, Sigma), 1% Triton X-100 (Sigma), and 20 μg / mL DNAse1 and 1 / 2 tablet. The resuspended pellets were frozen at -80°C for later purification. The lysates were clarified by centrifugation (4°C, 36,000 × g for 30 minutes), and the supernatant was incubated with glutathione-Sepharose 4B beads (GE Healthcare) at 4°C for 2 hours under gentle rotation, followed by centrifugation at 4,000 × g for 5 minutes. The supernatant was removed, and the beads were washed twice in 35 mL of 50 mM Tris, 125 mM NaCl, 2 mM DTT, and 0.01% Triton-X100. The beads were transferred to PD-10 Bio-Spin® chromatography columns (Bio-Rad) and washed further by three column volumes. Each column was sealed, and 0.075 U / μL of Novagen® was added for O / N cleavage at 4°C under gentle rotation. PICK1 was eluted on ice, and the absorbance at 280 nm was measured using a TECAN plate reader or NanoDrop3000. Protein concentration was measured using the Lambert-Beer law (A=εCl), which was εA280PICK1=32320 (cm×mol / L). -1 That was the case.
[0259] Example 2: Compound Synthesis PEG0-(HWLKV)2, PEG1-(HWLKV)2, PEG2-(HWLKV)2, PEG3-(HWLKV)2, PEG4-(HWLKV)2, Ac-(HWLK PEG4 V)2 and NPEG4-(HWLKV)2 were synthesized by solid-phase peptide synthesis as described in Bach et al., 2012.
[0260] NPEG4-(HWLKV)2 was myristoylated as described in Nissen et al., 2015, to obtain myr-NPEG4-(HWLKV)2.
[0261] Fluorescently labeled peptides (5-FAM) were prepared by direct conjugation of 5-FAM to an amine via an NPEG linker, or by conjugation of 5-FAM to the N-terminus of a peptide via a 6-aminohexanoic acid (Ahx) linker.
[0262] Example 3: Characterization of the behavior of myr-NPEG-(HWLKV)2 in solution To investigate the behavior of myr-NPEG4-(HWLKV)2 in solution, we performed size exclusion chromatography (SEC) in comparison with unconjugated NPEG4-(HWLKV)2 as a control. We also performed small-angle X-ray scattering (SAXS) analysis of myr-NPEG4-(HWLKV)2 in solution to obtain overall estimates of particle size and shape.
[0263] material and method: Size exclusion chromatography: Size exclusion chromatography was performed using an Akta purifier equipped with a Superdex200 Increase 10 / 300 column, with 500 μL of NPEG4-(HWLKV)2 or myr-NPEG4-(HWLKV)2 injected into the column at the indicated concentrations. Absorbance profiles were measured at 280 nm and plotted against elution volume using Graph Pad Prism 8.3.
[0264] Small-angle X-ray scattering analysis: A concentration series of myr-NPEG-(HWLKV)2 in the range of 0.18 mg / ml to 9.37 mg / ml was prepared in a buffer containing 50 mM Tris (pH 7.4) and 125 mM NaCl. Samples were measured at the P12 SAXS beamline, Petra III, DESY, Hamburg, Germany. Preliminary data processing, including radial averaging and conversion of data to absolute scale scattering intensity, I(q), as a function of the scattering vector q (q = 4πsin(θ) / λ (λ = half-scattering angle)), was performed at the beamline using standard procedures.
[0265] Modeling of SAXS data was performed in two ways: first using the distance distribution function, and then using a molecularly constrained core-shell model of polydisperse spheres. Briefly, it was assumed that the peptide aggregated into polydisperse spherical micelles, where the hydrophobic tails form the core, surrounded by hydrophilic parts (shells) within the spherical micelles. For modeling, scattering lengths of 2.26e-10 cm and 2.96e-11 cm were used for the head group and tail, respectively. These were calculated by counting the number of electrons in the molecular structure and multiplying by the scattering length of the electrons. For calculating the scattering length density, C 13 The molecular volume of an alkyl chain is given by Tanford's empirical formula.
[0266]
number
[0267] (In the formula, n c 377 Å, as can be estimated from the number of carbon atoms (i.e., 13 in this case). 3 It was presumed that the hydrophilic head group was the mass density of the soluble protein (i.e., 1.35 g / cm³). 3 This is the first estimate that is thought to have a mass density corresponding to 2078 Å. 3 The molecular volume was obtained. This value was adopted as a free parameter for fitting, and there was almost no variation in the fitting for different sample concentrations, resulting in a mass density of 1.39 g / cm³. 3 This corresponds to approximately 2010 Å.3 The molecular volume was refined. The excess scattering length density was then calculated for water (9.4e10 1 / cm³). 2 Using this molecular constraint model, the core and shell volumes are determined by the fitted number of aggregates, N agg They were internally linked through. Polydispersity is N agg The function was explained by a Gaussian function, which was truncated to ±3 sigma. The model module "PolydisperseMicelles" from the WillItFit software was used for fitting. As usual, small surface roughness and a small, constant background were also necessary for the model to converge.
[0268] The scattered data was integrated; binning was performed by subtracting the buffer using WillItRebin with a binning coefficient of 1. The distance distribution function (pddf) was used for intervals of [0.0122~0.4] Å. -1 Then, use bayesapp (http: / / www.bayesapp.org / ) to perform the fitting, and report the fitting parameters in the following data collection table.
[0269] [Table 1]
[0270] result: In this series of experiments, we tested myr-NPEG4-(HWLKV)2's ability to organize into higher-order oligomeric structures using SEC and SAXS.
[0271] Size exclusion chromatography (SEC) experiments were performed to demonstrate the concentration dependence of myr-NPEG4-(HWLKV)2 self-assembly compared to unconjugated NPEG4-(HWLKV)2, and it was observed that myr-NPEG4-(HWLKV)2 eluted at lower levels, suggesting a larger hydrodynamic radius and therefore larger molecular assemblies (Figure 1).
[0272] Small-angle X-ray scattering analysis: Using standard analysis techniques such as SAXS experiments to demonstrate the concentration dependence of myr-NPEG4-(HWLKV)2 self-assembly and analyze the pair-distance distribution function, we observed that myr-NPEG4-(HWLKV)2 appeared to organize into micelle structures with a radius of gyration (Rg) of 20–23.6 Å, consisting of 5–8 individual molecules (Figures 2a–2c). Since the pair-distance distribution function does not account for the negative scattering contribution of aliphatic groups, this analysis underestimates the number of molecules in the molecular assembly. Analysis of the data using the core-shell model described above suggested that myr-NPEG4-(HWLKV)2 assembled into micelle structures such as a spherical core-shell shape with an outer radius of 20–24 Å, containing 19–22 individual myr-NPEG4-(HWLKV)2 molecules.
[0273] conclusion This embodiment demonstrates that the PICK1 inhibitor of this disclosure can form higher-order structures such as micellar structures in solution.
[0274] Example 4: Binding of myr-NPEG4-(HWLKV)2 to PICK1 To test the binding of myr-NPEG4-(HWLKV)2 to recombinant PICK1, fluorescence polarization was performed. To verify the formation of higher-order complexes in PICK1 upon binding, size exclusion chromatography was performed.
[0275] material and method PICK1 was expressed and purified as described in Example 1.
[0276] Fluorescence polarization method: Fluorescence polarization was performed in competitive mode with fixed concentrations of protein and tracer (5FAM-NPEG4-(HWLKV)2, 5nM or 5FAM-HWLKV, 20nM) as the concentration of the indicated unlabeled peptide increased. Plates were incubated on ice for 2 hours in a black half-area Corning Black unbound surface 96-well plate. Fluorescence polarization was measured directly on an Omega POLARstar plate reader using an excitation filter at 488 nm and a long-pass fluorescence filter at 535 nm. Data were plotted using GraphPad Prism 8.3 and fitted to one-site competition. i,app The values were extracted.
[0277] Size exclusion chromatography: Size exclusion chromatography was performed using an Akta purifier with a Superdex200 Increase 10 / 300 column, where 500 μL of 40 μM PICK1 was loaded onto the column in the absence or presence of 10 μM myr-NPEG4-(HWLKV)2. Absorbance profiles were measured at 280 nm and plotted against elution volume using Graph Pad Prism 8.3.
[0278] result In this series of experiments, we tested myr-NPEG4-(HWLKV)2's ability to bind to recombinant purified PICK1 in a complex as demonstrated by SEC, using fluorescence polarization, and its ability to induce higher-order oligomers of PICK1 (Figure 4).
[0279] Fluorescence polarization (FP) experiments were performed to determine the binding affinity to PICK1. Competitive experiments using 5FAM-NPEG4-(HWLKV)2 or 5FAM-HWLKV as the fluorescence tracer showed a >1000-fold increase in affinity of myr-NPEG4-(HWLKV)2 compared to HWLKV (Ki,app=6998nM, SEM interval [4972~9849]nM, n=3) (Ki,app=3.0nM, SEM interval [2.3~3.8]nM, n=6), and a >50-fold increase in affinity of myr-NPEG4-(HWLKV)2 compared to NPEG4-(HWLKV)2 (Ki,app=179nM, SEM interval [169~189], n=6) (Figure 3).
[0280] Size exclusion chromatography was performed to evaluate the behavior of myr-NPEG4-(HWLKV)2 in solution in complex with PICK1. The elution volume suggested that myr-NPEG4-(HWLKV)2 forms a higher-order oligomeric structure of PICK1 upon binding (Figure 4).
[0281] conclusion This embodiment demonstrates that the PICK1 inhibitor of this disclosure exhibits high binding affinity to PICK1. Lipid coupling to a divalent peptide ligand provides a >50-fold increase in affinity compared to unconjugated NPEG4-(HWLKV)2.
[0282] This embodiment further demonstrates that the PICK1 inhibitors of this disclosure can induce a higher-order structure of PICK1 upon binding. Inhibition of protein function may be attributable to such induction of the higher-order structure of PICK1.
[0283] Example 5: Optimization of PICK1-binding peptide ligand sequences for identifying high-affinity binders To test the rigor of the PICK1 PDZ binding motif in the DAT-C5(HWLKV) sequence (i.e., positions X1-X5) and to identify a putative peptide with better affinity, we performed initial studies using fluorescence-polarized binding of 95 different pentapeptides, each containing a residue in the HWLKV sequence substituted with one of 19 other native amino acids, to purified PICK1.
[0284] Furthermore, we utilized the data obtained from the above experiments as guidance to design 52 different penta-, tetra-, and tripeptides derived from amino acid combination substitutions. To validate the putative peptides with better affinity, their binding affinity to purified PICK1 was studied by fluorescence polarized coupling assay.
[0285] material and method: Fluorescence polarization method: Fluorescence polarization was performed in competitive mode at fixed concentrations of protein and tracer (5FAM-HWLKV, 20 nM) as the concentration of the indicated unlabeled peptide increased. Plates were incubated on ice for 20 minutes in a black half-area Corning Black unbound surface 96-well plate, and fluorescence polarization was measured directly on an Omega POLARstar plate reader using an excitation filter at 488 nm and a long-pass fluorescence filter at 535 nm. Data were plotted using GraphPad Prism 6.0, fitted to one-site competition, and finally correlated with all plotted HWLKV affinity. d The values were extracted.
[0286] result Single substitution experiment: Substitutions at X1 and X3 were mostly destructive to binding (shown in lighter shades), except for substitutions of V and I at X3, and these increased affinity (Figure 5). At position X2, substitutions of R, C, I, and L all increased affinity, and most substitutions were tolerated. Similarly, substitutions at X4 and X5 were generally well tolerated, with the notable exception of positively charged residues at X4, which decreased affinity. Substitutions of Y, E, S, Q, C, A, and G at position X4 increased affinity. Most substitutions (including Y, F, T, S, Q, N, C, V, M, I, G, and A) increased affinity at position X5, although some substitutions impaired solubility.
[0287] 52 combination peptides: Based on double substitutions in class II bonding motifs, we found that many combinations were well tolerated, and generally N at position X1, S / E at position X2, and R at position X4 had better or non-perturbative affinities, while F at position X1 was generally not well tolerated (Figure 6).
[0288] conclusion This example demonstrates that optimizing the HWLKV sequence by amino acid substitution provides a peptide ligand that exhibits equivalent and even higher affinity to PICK1.
[0289] Example 6: Mutant forms of PEG and mutant forms of the attachment site of PEG to peptide ligands In this series of experiments, we tested various PEGs containing divalent peptide ligands against purified PICK1. x We wanted to test the affinity of (x=0~4 ethylene glycol moieties) (Figure 7). In addition, we also wanted to test the affinity of purified PICK1 when PEG4 uses different linker bonds linked to the lysine (K) amino acid side chain of sequence HWLKV (Figure 7; ac-(HWLKV) PEG4 V)2.
[0290] material and method PICK1 was expressed and purified as described in Example 1.
[0291] Fluorescence polarization method: Fluorescence polarization method is used with unlabeled PEG. x The study was run in competition mode with fixed concentrations of protein and tracer (5FAM-NPEG4-(HWLKV)2, 5nM) as the concentration of -(HWLKV)2 increased. Plates were incubated on ice for 2–4 hours in a black half-area Corning Black unbound surface 96-well plate, and fluorescence polarization was measured on an Omega POLARstar plate reader using an excitation filter at 488 nm and a long-pass fluorescence filter at 535 nm. Data were plotted using GraphPad Prism 6.0 and fitted to one-site competition. i The values were extracted, correlated with the affinity of the HWLKV peptide, and finally plotted as a factorial affinity increase.
[0292] result To test the minimum distance required between two identical pentapeptides, we decided to test different PEG linker lengths and positions. We observed slight variations in affinity between PEG linkers of different lengths, all of which resulted in enhanced PICK1 affinity compared to the HWLKV peptide (Figure 8).
[0293] Furthermore, we observed that attachment of the PEG4 linker to the X4 lysine side-chain amine instead of the N-terminal amine did not significantly alter the affinity compared to PEG4-HWLKV.
[0294] conclusion This embodiment demonstrates that variations in linker length and attachment site are sufficiently permissible in the PICK1 inhibitor of this disclosure.
[0295] Example 7: Evaluation of the efficacy of myr-NPEG4-(HWLKV)2 in inflammatory pain In this series of experiments, we aim to evaluate the efficacy of myr-NPEG4-(HWLKV)2 in alleviating inflammatory pain in a complete Freund's adjuvant (CFA) model in mice.
[0296] material and method. Inflammatory pain: Animals were acclimated to the laboratory for at least 60 minutes before the start of the experiment. Mechanical pain thresholds were determined by von Fry measurements of both hind legs. Injury was induced in the right hind leg, and the contralateral left hind leg was used as an internal control of the animal. Von Fry filaments ranging from 0.04g to 2g (g = grams - force) (0.04, 0.07, 0.16, 0.4, 0.6, 1.0, 1.4, 2.0) were used to determine the mechanical pain threshold. In the experiment, the filaments were applied in ascending order to the anterior-central plantar surface of the hind leg. Mice were placed in a PVC plastic box (11.5cm × 14cm) on a wire mesh and acclimated for 30 minutes before acclimatization. Each von Fry hair was applied 5 times with sufficient rest periods between each application, and the number of retractions was recorded. The retraction threshold was determined as the von Fry filament that elicited at least 3 positive tests out of 5 applications with two consecutive filaments. A positive test was defined as sudden paw retraction, flinching, and / or paw licking induced by filament. Inflammatory pain was induced by unilateral injection of 50 μL of undiluted complete Freund's adjuvant (CFA) (F5881, Sigma) into the plantar surface of the right hind paw, while control mice were injected with the same volume of 0.9% saline (Bee Braun, Germany). All plantar injections were performed using an insulin needle (0.3 mL BD Micro-Fine) while the animals were under isoflurane anesthesia (2%) for up to 60 seconds. Von Frey was applied for up to 11 days after unilateral CFA injection, depending on the experiment. myr-NPEG4-(HWLKV)2 was administered at different concentrations (2 μmol / kg, 10 μmol / kg, or 50 μmol / kg) via different routes (intrathecal (it (7 μL)) or sc (10 μL / g)). Statistical analysis was performed using GraphPad Prism 6.0. A two-way repeated measures ANOVA was followed by Bonferroni's post-hoc test. The significance level was set at p<0.05.
[0297] result: The following demonstrates the efficacy of myr-NPEG4-(HWLKV)2 in alleviating inflammatory pain in CFA models using three different treatments.
[0298] On day 0, mice were i.pl. injected with 50 μL of CFA or saline into their right hind leg. On day 2, mice were sc-injected with 50 μmol / kg (10 μL / gram) of myr-NPEG4-(HWLKV)2 or saline. Induced pain was tested using von Flei filaments before injection and at 1, 5, and 24 hours after injection. Two-way ANOVA and subsequent Bonferroni post-hoc test revealed a significant overall effect of myr-NPEG4-(HWLKV)2, with significant pain relief at 1 hour post-injection. In addition, the data revealed that injection of saline into the hind leg instead of CFA was ineffective, and the effect of CFA on hyperalgesia disappeared by day 11 post-injection (Figure 9a).
[0299] On day 0, mice were i.pl. injected with 50 μL of CFA or saline into their right hind leg. On day 2, hyperalgesia was confirmed using von Frye filaments, and mice were sc-injected with 2 μmol / kg, 10 μmol / kg, or 50 μmol / kg (10 μL / gram) of myr-NPEG4-(HWLKV)2 or saline (10 μL / gram). Induced pain was retested at 1, 5, and 24 hours post-injection using von Frye filaments. Two-way ANOVA and subsequent Bonferroni post-hoc tests revealed a significant overall effect of myr-NPEG4-(HWLKV)2, with significant pain relief up to 5 hours post-injection for the highest concentration tested, and significant pain relief at 1 hour post-injection for the two lower concentrations (Figure 9b).
[0300] On day 0, mice were i.pl. injected with 50 μL of CFA or saline into their right hind leg. On day 2, hyperalgesia was confirmed using von Frey filaments, and mice were intrathecally injected with 20 μM myr-NPEG4-(HWLKV)2 or saline in a volume of 7 μL. Induced pain was retested at 1, 5, and 24 hours post-injection using von Frey filaments. Two-way ANOVA followed by Bonferroni's post-hoc test revealed a significant overall effect of myr-NPEG4-(HWLKV)2, with significant pain relief at 1 and 5 hours post-administration of myr-NPEG4-(HWLKV)2, but no effect at 24 hours post-administration (Figure 9c).
[0301] conclusion This example demonstrates that myr-NPEG4-(HWLKV)2 significantly alleviates inflammatory pain in a CFA model of inflammatory pain, as evidenced by an increase in the foot withdrawal threshold (Figures 9a-9c). In addition, the foot withdrawal threshold remained unchanged in the uninjured contralateral foot. myr-NPEG4-(HWLKV)2 was effective in alleviating pain after subcutaneous injection of two doses (Figures 9a-9b). Furthermore, myr-NPEG4-(HWLKV)2 alleviated inflammatory pain after intrathecal injection (Figure 9c), confirming that myr-NPEG4-(HWLKV)2 inhibits central sensitization.
[0302] Example 8: Evaluation of the efficacy of myr-NPEG4-(HWLKV)2 in neuropathic pain In this experiment, we aim to evaluate the efficacy of myr-NPEG4-(HWLKV)2 in alleviating neuropathic pain in a mouse model of nerve branch ligation injury (SNI).
[0303] material and method Neuropathic pain. SNI pain experiments were conducted by Phenotypic Expertise-Pain and CNS Behavior CRO under the supervision of Dr. Stephane Gaillard (CEO). The study was performed on 8-week-old C57Bl6J male mice (Charles River). Nerve branch ligation injury surgery was performed on anesthetized mice. The common fibular and distal tibial branches of the sciatic nerve were ligated and transected, leaving the sural branch intact. Seven days after surgery, a decrease in the threshold response to the ipsilateral hind leg von Frey filament was confirmed using a von Frey filament corresponding to the neuropathic pain state. The contractile threshold response of manipulated mice was measured using a calibrated von Frey filament ("up / down" method), and the 50% threshold (g) was calculated. Experimenters were blinded to the treatment of the mice. The contraction threshold was measured before surgical removal and again at 0, 1, 2, 3, 4, and 6 hours after drug administration, and on day 7. All compounds were diluted in PBS and administered at 10 μL / g sc. Statistical analysis was performed using GraphPad Prism 6.0. A two-way repeated measures ANOVA was followed by Bonferroni's post-hoc test. The significance level was set at p<0.05.
[0304] result: Mice underwent surgery to induce partial nerve damage by severing the peroneal and tibial nerves, resulting in hypersensitivity of the remaining sural nerve (SNI). Seven days later, hyperalgesia was confirmed using von Flei filaments, and mice were sc-injected with either 2 μmol / kg or 10 μmol / kg (10 μL / gram) myr-NPEG4-(HWLKV)2 or physiological saline (10 μL / 1 gram mouse). Induced pain was re-tested at 1, 2, 3, 4, and 6 hours post-injection using von Flei filaments. Two-way ANOVA followed by Bonferroni post-hoc test revealed a significant overall effect of myr-NPEG4-(HWLKV)2, with significant pain relief up to 3 hours post-injection for the highest concentration tested, and no significant pain relief for lower concentrations.
[0305] conclusion This example demonstrates that myr-NPEG4-(HWLKV)2 significantly alleviates neuropathic pain in a SNI model of neuropathic pain, as evidenced by the increased paw retraction threshold in treated mice. Furthermore, the paw retraction threshold remained unchanged in the uninjured contralateral paw. This confirms that myr-NPEG4-(HWLKV)2 is effective in dose-dependently alleviating pain after subcutaneous injection (Figure 10).
[0306] Example 9: Evaluation of the efficacy of NPEG4-(HWLKV)2 in neuropathic pain In this example, the objective was to evaluate the efficacy of NPEG4-(HWLKV)2 (without aliphatic chains, PD5) in alleviating neuropathic pain after nerve branch ligation injury (SNI) in a mouse model.
[0307] material and method Neuropathic pain. The study was performed on 8-week-old C57Bl6J male mice (Charles River). Nerve branch ligation injury surgery was performed on anesthetized mice. The common fibular and distal tibial branches of the sciatic nerve were ligated and transected, while the sural branch was left intact. Nine days after surgery, a decrease in the threshold response to the von Frey filament in the ipsilateral hind leg was confirmed using a von Frey filament corresponding to the neuropathic pain state. The contractile threshold response of the manipulated mice was measured using a calibrated von Frey filament ("up / down" method), and the 50% threshold (g) was calculated. Experimenters were blinded to the treatment of the mice. The contractile threshold was measured before surgery and again on day 9 at 0, 1, 2, 3, 4, and 6 hours after drug administration. All compounds were diluted in PBS, and 10 μmol / kg (10 μL / gram) of NPEG4-(HWLKV)2 was administered via sc at 10 μL / g. Statistical analysis was performed using GraphPad Prism 6.0. A two-way repeated measures ANOVA was followed by Bonferroni's post-hoc test. The significance level was set at p<0.05.
[0308] result: Mice underwent surgery to induce partial nerve damage by severing the peroneal and tibial nerves, resulting in hypersensitivity of the remaining sural nerve (SNI). Nine days later, hyperalgesia was confirmed using von Flei filaments, and mice were sc-injected with 10 μmol / kg (10 μL / gram) NPEG4-(HWLKV)2(PD5). Induced pain was re-tested at 1, 2, 3, 4, and 6 hours post-injection using von Flei filaments. Two-way ANOVA and subsequent Bonferroni post-hoc test did not reveal a significant effect of treatment with aliphatic-free NPEG4-(HWLKV)2 (Figure 11). For comparison, the myr-NPEG4-(HWLKV)2 and vehicle groups from Example 8 (Figure 10) are shown by dashed lines.
[0309] conclusion This example demonstrates that, in an SNI model of neuropathic pain, NPEG4-(HWLKV)2 (without aliphatic chains) does not significantly alleviate neuropathic pain, as evidenced by the increased paw retraction threshold in treated mice.
[0310] Example 10: Evaluation of the efficacy of myr-NPEG4-(HWLKV)2 in chronic neuropathic pain In this experiment, the objective was to evaluate the efficacy of myr-NPEG4-(HWLKV)2 in alleviating neuropathic pain one year after a mouse model of nerve branch ligation injury (SNI).
[0311] material and method Neuropathic pain. The study was performed on 8-week-old C57Bl6J male mice (Charles River). Nerve branch ligation injury surgery was performed on anesthetized mice. The common fibular and distal tibial branches of the sciatic nerve were ligated and transected, leaving the sural branch intact. Two days after surgery, a decrease in the threshold response to von Frey filaments in the ipsilateral hind leg was confirmed using von Frey filaments corresponding to the neuropathic pain state. Mice were tested with von Frey monthly, and the hyperalgesic response persisted at 52 weeks.
[0312] The contractile threshold response of manipulated mice was measured using a calibrated von Frye filament ("up / down" method), and the 50% threshold (g) was calculated. Experimenters were blinded to the treatment of the mice. Contractile thresholds were measured at 2 and 5 hours post-injection. All compounds were diluted in PBS and administered at 10 μL / g, 30 μmol / kg sc. Statistical analysis was performed using GraphPad Prism 6.0. Dunnett's multiple comparison test followed one-way ANOVA. ****, p<0.0001.
[0313] result: Mice underwent surgery to induce partial nerve damage by severing the peroneal and tibial nerves, resulting in hypersensitivity of the remaining sural nerve (SNI). Two days later, hyperalgesia was confirmed by the use of von Frey filaments (Figure 12). This remained unchanged after 52 weeks. Mice were injected with 30 μmol / kg (10 μL / gram) myr-NPEG4-(HWLKV)2 (10 μL / 1 gram mouse) via sc injection. Induced pain was re-tested at 2 and 5 hours post-injection using von Frey filaments. One-way ANOVA followed by Dunnett's multiple comparison test revealed a very significant effect of treatment at 5 hours (p<0.0001).
[0314] conclusion This example demonstrates that in a SNI model of neuropathic pain, myr-NPEG4-(HWLKV)2 significantly alleviates neuropathic pain for a full year after induction of SNI injury, as evidenced by the increased paw retraction threshold in treated mice.
[0315] Example 11: Evaluation of the efficacy of myr-NPEG4-(HWLKV)2 in diabetic neuropathy In this experiment, the objective was to evaluate the efficacy of myr-NPEG4-(HWLKV)2 in alleviating diabetic neuropathy using a streptozocin (STZ) model of type 1 diabetes.
[0316] material and method Diabetic neuropathy (STZ) model. Diabetes was induced by a single IP injection of 200 μg / mL streptozocin solution (100 μl / 10 g, Sigma-Aldrich S0130, batch #WXBB7152V). Blood glucose levels were tested before injection and 7 days after injection. All injected mice presented blood glucose levels >350 mg / dL at D+7 and were subsequently used for analgesic testing of the compound at D+14. One mouse needed to be euthanized 7 days after injection.
[0317] The contractile threshold response of manipulated mice was measured using a calibrated von Frey filament ("up / down" method), and the 50% threshold (g) was calculated. Experimenters were blinded to the treatment of the mice. Thirteen days after surgery, a decrease in the threshold response to the ipsilateral hind leg von Frey filament was confirmed using a von Frey filament corresponding to diabetic neuropathy. After injection of myr-NPEG4-(HWLKV)2, the contractile threshold was measured at 1, 2, 4, and 6 hours, and again on day 15. The compound was diluted in PBS (vehicle) and administered at the indicated doses, 10 μL / g (gabapentin, 5 MPK) sc. Statistical analysis was performed using GraphPad Prism 6.0. One-way ANOVA followed by Dunnett's multiple comparison test. ****, p<0.0001.
[0318] result: Seven days after STZ administration, all mice showed a rapid increase in blood glucose levels (from 197.4+ / -4.4 mg / dL to 533.5+ / -10.4 mg / dL; see appendix) confirming the diabetic status of the mice. As shown in Figure 13, 13 days after STZ injection, diabetic-induced neuropathic pain was clearly established by a decrease in the mechanical response threshold (mechanical allodynia). Pregabalin (5MPK) administration induced a significant increase in the mechanical response threshold compared to the vehicle group (p<0.001 at 1, 2, and 4 hours post-administration) with a maximum reversal of 84.7±10.5% from baseline at +2 hours. Both myr-NPEG4-(HWLKV)2(mPD5) solutions at 2 μmol / kg and 10 μmol / kg induced a significant increase in the mechanical response threshold compared to the vehicle group (p=0.006 at 1 HR and p=0.003 at 2 HR for the lowest concentration; p<0.001 at 1 HR and 2 HR for the 10 μmol / kg solution, and p<0.006 at 4 HR). Maximum reversal was reached 2 hours after administration (49.2±7.9% and 67.3±4.5% of baseline for the 2 μmol / kg and 10 μmol / kg solutions, respectively). Interestingly, we also observed statistically significant differences between the two groups treated with mPD5 at 1 HR and 2 HR (p=0.013 and p=0.008, respectively).
[0319] conclusion In this study, we tested the analgesic effect of myr-NPEG4-(HWLKV)2 on an STZ-induced neuropathic pain model in mice. Interestingly, we observed a potent and long-lasting effect up to 4 hours after administration at 10 μmol / kg. At the same time, we also observed a dose-dependent effect of the peptide, which was weaker at a dose of 2 μmol / kg. Notably, no visible side effects were observed.
[0320] Example 12: Evaluation of the efficacy of myr-NPEG4-(NSVRV)2, myr-NPEG4-(SVRV)2, and myr-NPEG4-(LRV)2 in inflammatory pain. In this series of experiments, the objective was to evaluate the efficacy of mutants to PDZ domain binding sequences, as defined by the peptide optimization described in Example 5 for alleviating inflammatory pain in a complete Freund's adjuvant (CFA) model in mice. This defines the conversion from screening to in vivo efficacy in Example 5 and demonstrates the effect of shorter binding motifs (C4 and C3).
[0321] material and method. Inflammatory pain (CFA model): Animals were acclimated to the laboratory for at least 60 minutes before the start of the experiment. Mechanical pain thresholds were determined by von Frye measurements of both hind legs. Injury was induced in the right hind leg, and the contralateral left hind leg was used as an internal control of the animal.
[0322] Von Frye filaments ranging from 0.04g to 2g (g = grams - force) (0.04, 0.07, 0.16, 0.4, 0.6, 1.0, 1.4, 2.0) were used to determine the mechanical pain threshold. In the current experiment, the filaments were applied in ascending order to the anterior-central plantar surface of the hind paw. Mice were placed in a PVC plastic box (11.5cm × 14cm) on a wire mesh and allowed to acclimate for 30 minutes before the test. Each Von Frye hair was applied five times with sufficient rest periods between applications, and the number of retractions was recorded. The retraction threshold was determined as the Von Frye filament that elicited at least three positive tests out of five applications with two consecutive filaments. A positive test was defined as a sudden retraction of the paw, flinching, and / or paw licking induced by the filament.
[0323] Inflammatory pain was induced by unilateral injection of 50 μL of undiluted complete Freund's adjuvant (CFA) (F5881, Sigma) into the plantar surface of the right hind foot, while control mice were injected with the same volume of 0.9% saline (B. Braun, Germany). All plantar injections were performed using an insulin needle (0.3 mL BD Micro-Fine) while the animals were under isoflurane anesthesia (2%) for up to 60 seconds. Von Frey was applied for up to 6 days after unilateral CFA injection, depending on the experiment. The peptide was administered sc at (10 μL / g) and different concentrations (0.4 μmol / kg and 2 μmol / kg). Statistical analysis was performed using GraphPad Prism 6.0. Dunnett's post-hoc test followed by two-way repeated measures ANOVA. The significance level was set at p < 0.05.
[0324] result: On day 0, mice were i.pl. injected with 50 μL of CFA or physiological saline into their right hind leg. On day 2 after CFA injection, mice were sc-injected with 0.4 μmol / kg (10 μL / gram) of myr-NPEG4-(HWLKV)2, myr-NPEG4-(NSVRV)2, myr-NPEG4-(SVRV)2, or myr-NPEG4-(LRV)2. On day 5, mice were sc-injected with 2 μmol / kg (10 μL / gram) of myr-NPEG4-(HWLKV)2, myr-NPEG4-(NSVRV)2, myr-NPEG4-(SVRV)2, or myr-NPEG4-(LRV)2. At this concentration, myr-NPEG4-(NSVRV)2 did not completely dissolve. On both days 2 and 5, induced pain was tested using von Frye filaments before injection and at 1, 5, and 24 hours after injection. Separate two-way ANOVA and subsequent Dunnett post-hoc analysis for each day of administration revealed that the highest affinity compound, myr-NPEG4-(NSVRV)2, relieved pain at a Sc dose of 0.4 μmol / kg, and furthermore, both myr-NPEG4-(HWLKV)2 and myr-NPEG4-(SVRV)2 relieved pain at a Sc dose of 2.0 μmol / kg (Figure). 14At this concentration, myr-NPEG4-(NSVRV)2 did not dissolve completely. Myr-NPEG4-(LRV)2 showed a tendency towards pain relief at this dose, but this was not statistically significant in the experiment (Figure 14).
[0325] conclusion This example demonstrates that, in a CFA model of inflammatory pain, myr-NPEG4-(NSVRV)2, myr-NPEG4-(SVRV)2, or myr-NPEG4-(LRV)2, as well as myr-NPEG4-(HWLKV)2, alleviate inflammatory pain at 2 μmol / kg (10 μL / gram), as evidenced by an increase in the foot retraction threshold (Figure 14). This confirms the efficacy of shorter PICK1 PDZ binding motifs (C4 and C3), as well as the C5 PICK1 PDZ binding motif, and is consistent with the affinity observed in Example 5. In addition, myr-NPEG4-(NSVRV)2 (Example 5), which retains the best-affinity peptide (NSVRV) for optimization, showed significant pain relief at 0.4 μmol / kg (10 μL / gram).
[0326] Example 13: Evaluation of the efficacy of myr-NPEG4-(HWLKV)2 in the alleviation of spontaneous inflammatory pain. The objective of this experiment was to evaluate the ability of myr-NPEG4-(HWLKV)2 to alleviate ongoing and spontaneous pain, not only by alleviating pain induced by the experimenter touching the inflamed foot, but also by using the preference of a single exposure site. This is considered to be of paramount importance for clinical interpretation.
[0327] material and method. Inflammatory pain (CFA model): Animals were acclimatized to the laboratory for at least 60 minutes before the start of the experiment. Mechanical pain thresholds for both hind legs were determined by von Frye measurements. Injury was induced in the right hind leg, and the contralateral left hind leg was used as an internal control of the animal. Von Frye filaments ranging from 0.04 g to 2 g (g = grams - force) (0.04, 0.07, 0.16, 0.4, 0.6, 1.0, 1.4, 2.0) were used to determine the mechanical pain threshold. In the experiment, the filaments were applied in ascending order to the anterior-central plantar surface of the hind leg. Mice were placed in a PVC plastic box (11.5 cm × 14 cm) on a wire mesh and acclimatized for 30 minutes before the test. Each von Frye filament was applied 5 times with sufficient rest periods between each application, and the number of retractions was recorded. The retraction threshold was determined as the von Frye filament that elicited at least 3 positive tests out of 5 applications with two consecutive filaments. A positive test was defined as sudden paw retraction, flinching, and / or paw licking induced by the filament. Inflammatory pain was induced by unilateral injection of 50 μL of undiluted complete Freund's adjuvant (CFA) (F5881, Sigma) into the plantar surface of the right hind paw. All plantar injections were performed using an insulin needle (0.3 mL BD Micro-Fine), while the animals were anesthetized under isoflurane (2%) for up to 60 seconds. Von Frey confirmed hypersensitivity before CFA injection, 2 days after CFA injection, and 5 days after CFA injection, both before and after the single exposure site preference experiment described below. Statistical analysis was performed using GraphPad Prism 6.0. Student's t-test. The significance level was set at p < 0.05.
[0328] Prioritization of a single exposure site (sePP): The sePP experiment was conducted in a rectangular apparatus with three sections: a central neutral zone (11.5 × 24 cm) and two elongated sections (28 × 24 cm) at the ends with different floor textures and wall patterns. During the exposure session, the sections were separated from each other by two off-white Plexiglas® partitions (24 × 40 cm), which were removed on the test day.
[0329] The sePP protocol was performed over three days, with exposure sessions on the first two days and testing on the third day. On all three days, mice were allowed to acclimate to the room for at least 60 minutes before the start of the experiment. mPD5 was always paired with a compartment that had gray walls and a perforated floor, which had previously been shown to be the least desirable compartment. All mice from the cages were tested simultaneously, but not all received the same treatment.
[0330] On the exposure day, mice were weighed and sc-injected with either peptide (30 μmol / kg) or vehicle (10 μL / g), and immediately placed in designated compartments for 60 minutes. The test group was exposed to peptide in the least favorable compartment and to vehicle (PBS) in the favorable compartment, while the control group was injected with vehicle in both compartments.
[0331] On day 3, for the priority test, Plexiglas® was removed, and the mice were allowed to move freely between the three compartments for 20 minutes. The time spent in different compartments was measured using Esovision (Noldus, Wageningen, Netherlands). Additional experiments were performed on undamaged animals and did not show mPD5-dependent changes in priority.
[0332] result: A single exposure to myr-NPEG4-(HWLKV)2 is sufficient to alter the site preference of CFA-injured animals. In the preference test, myr-NPEG4-(HWLKV)2-treated animals spent significantly longer periods in the myr-NPEG4-(HWLKV)2-treated compartment compared to vehicle-treated control mice (Figures 15A and 15B), suggesting a preference for the compartment of animals treated with myr-NPEG4-(HWLKV)2. For clarification, the change in preference was due to pain relief, and not because the peptide itself altered their preference. The exact same experiment, performed on uninjured (naive) mice, showed no change in preference in myr-NPEG4-(HWLKV)2-treated animals. This further suggests a lack of abuse potential for myr-NPEG4-(HWLKV)2.
[0333] Conclusion: This example demonstrates that mice with inflammatory pain shift priority to the chamber that previously received myr-NPEG4-(HWLKV)2, suggesting that the mice recognize the drug alleviates progressive and spontaneous pain. This is considered most important for translational potential, as most of the patient's distress is associated with progressive pain.
[0334] Example 14: Plasma concentrations of mPD5 at different concentrations compared to Tat-PD5 The objectives of this experiment were to evaluate the plasma concentration and lifetime of myr-NPEG4-(HWLKV)2, and to determine whether acrylication of myr-NPEG4-(HWLKV)2 extends its plasma half-life compared to its parent molecule, Tat-NPEG4-(HWLKV)2.
[0335] material and method: The mPD5 curves for myr-NPEG4-(HWLKV)2 exposure were determined by WUXI and DMPK. Three male C57BL / 6N mice (fasted) were injected with Sc at various mPD5 concentrations (2 μmol / kg, 10 μmol / kg, and 50 μmol / kg) in sterile PBS. Blood samples were collected at 30 minutes, 1 hour, 2 hours, 5 hours, and 12 hours, and the plasma was subjected to LC-MS. Three points on the downslope were determined from the three points in the removal phase.
[0336] Determination of plasma exposure to biotinylated Tat-NPEG4-(HWLKV)2 Blood sample collection. Biotinylated TAT-di-PEG4-DATC5 (biot-TPD5; 34 mg / kg = 10 μmol) or biotinylated myr-di-PEG4-DATC5 (biot-mPD5; 10 μmol), diluted in 0.9% NaCl, was initially injected into 8-week-old male C57bl6N mice (18 mice in total). Blood samples were collected at 15 minutes, 30 minutes, 1 hour, 2 hours, and 6 hours later using BD Vacutainer® K3 EDTA tubes containing aprotinin (BD Diagnostics) (blood samples from 6 mice at each time point). The blood samples were centrifuged at 3500 RPM for 15 minutes at 4°C, and the plasma was collected in new tubes and frozen at -20°C.
[0337] ELISA. A 96-well NUNC immobilizer plate (catalog number 436006) was coated with 15 μg / mL biotinylated albumin (Sigma-Aldrich, product number A8549) diluted in 100 mM sodium carbonate buffer (pH 9.6) and incubated on a shaker at room temperature for 2 hours. After incubation, the plate was washed three times with PBS-T (1× phosphate-buffered saline containing 0.1% TWEEN® 20 (Sigma-Aldrich)), with each wash step performed overnight on a shaker at room temperature. Diluted HRP-conjugated streptavidin (DAKO, citation no. P0397, 0.83 g / L) (1:5000) containing 0.1% PBST was mixed with biot-TPD5 at different dilutions (10× and 20×) in a separate round-bottom 96-well plate (Thermo Scientific) and incubated on a shaker for 20 minutes. The solution (100 μL / well) was placed in the coated 96-well plate and incubated at room temperature for 1 hour. After incubation, the plate was washed three times with PBS-T and developed in 100 μL of TMB Plus (Sigma, SLBT4708, T0440-1L) for 3-5 minutes. Development was stopped by adding 100 μL of 0.2 M sulfuric acid (H2SO4). The plates were read at 450 nm (and 570 nm) on a Wallac VICTOR2 1420 multilabel counter from PerkinElmer (Bizør, Denmark). The measured absorbances were calibrated against a standard curve generated from a standard dilution of biot-TPD5.
[0338] result: For myr-NPEG4-(HWLKV)2, we observed an initial increase in plasma concentration, reaching peak concentration after 1 hour (1446±106 ng / ml after injection of 3.75 mg / kg (2 μmol / kg); 6173±508 ng / ml after injection of 18.8 mg / kg (10 μmol / kg); 20258±642 ng / ml after injection of 93.8 mg / kg (50 μmol / kg)), followed by a linear removal phase at a rate of one order of magnitude on a semi-logarithmic scale. Both the peak dose and the area under the curve were T 1 / 2The concentration increased linearly with the dose (0.50±0.07 hours after injection of 3.75 mg / kg (2 μmol / kg); 0.59±0.07 hours after injection of 18.8 mg / kg (10 μmol / kg); 0.84±0.03 hours after injection of 93.8 mg / kg (50 μmol / kg)) (Figure 16). For biotinylated Tat-NPEG4-(HWLKV)2 (10 μmol / kg), we observed an increase in plasma concentration followed by a nonlinear removal profile with a peak at 30 minutes and a slowdown in the later stages. The maximum concentration was similar to that observed for myr-NPEG4-(HWLKV)2 (10 μmol / kg) (Figure 16).
[0339] Conclusion: myr-NPEG4-(HWLKV)2 is distributed into the plasma in a dose-dependent manner after Sc administration and is removed at a rate of one order of magnitude with a half-life of 30-45 minutes. This is similar to that of Tat-NPEG4-(HWLKV)2, consistent with the effect of its behavior, and indicates that acrylication of myr-NPEG4-(HWLKV)2 does not exert its effect by extending plasma exposure or lifespan.
[0340] Example 15: Evaluation of solubility and stability of myr-NPEG4-(HWLKV)2 The objective was to determine the solubility, which is important for the preferred (subcutaneous) administration route, and the chemical stability, which is critical for the shelf life of myr-NPEG4-(HWLKV)2.
[0341] material and method: Solubility was determined by visual inspection of samples dissolved in 10 mM PBS at increasing concentrations. Stability was examined by leaving myr-NPEG4-(HWLKV)2 in PBS at 5°C and 25°C for 30 days, followed by HPLC-UV-MS analysis using REDGLEAD at four concentrations: 2 μM, 20 μM, 50 μM, and 200 μM.
[0342] result: Visual inspection revealed that the solubility of myr-NPEG4-(HWLKV)2 is at least 250 mg / ml (130 mM) (Figure 17); this may be due to the micelle structure.
[0343] No degradation was observed, and the purity was determined to be >98% for the 200 μM and 50 μM samples. For the 20 μM and 2 μM samples, degradation was not observed in either due to low absorption, but the purity could not be definitively determined. Peptide mPD5 is chemically stable in the vehicle composition for at least 30 days at +5°C and +25°C. Mass was confirmed for all samples, including standard samples for the calibration curve.
[0344] [Table 2]
[0345] Conclusion: myr-NPEG4-(HWLKV)2 exhibits excellent stability, which is considered sufficient for human subcutaneous administration (maximum dose of 800 μl) while maintaining the observed efficacy. In addition, its good stability suggests that the compound meets the requirements for shelf life.
[0346] Example 16: Variations of lipophilic aliphatic chains The objective of this series of experiments was to evaluate the efficacy and extension of action by aliphatic chain substations in a mouse complete Freund's adjuvant (CFA) model.
[0347] material and method. Inflammatory pain (CFA model): Inflammatory pain was induced by unilateral injection of 50 μL of undiluted complete Freund's adjuvant (CFA) (F5881, Sigma) into the plantar surface of the right hind leg, while control mice were injected with the same volume of 0.9% saline (B. Braun, Germany). All plantar injections were performed using an insulin needle (0.3 mL BD Micro-Fine) while the animals were under isoflurane anesthesia (2%) for up to 60 seconds. Injury was induced in the right hind leg, and the contralateral left hind leg was used as an internal control of the animals.
[0348] Animals were allowed to acclimate to the laboratory for at least 60 minutes before the start of the experiment. The mechanical pain threshold was determined by Von Fry measurements of both hind feet. Von Fry filaments ranging from 0.04g to 2g (g = grams - force) (0.04, 0.07, 0.16, 0.4, 0.6, 1.0, 1.4, 2.0) were used to determine the mechanical pain threshold. In the experiment, the filaments were applied in ascending order to the anterior-central plantar surface of the hind foot. Mice were placed in a PVC plastic box (11.5cm × 14cm) on wire mesh and allowed to acclimate for 30 minutes before the test. Each Von Fry hair was applied 5 times with sufficient rest periods between each application, and the number of retractions was recorded. The retraction threshold was determined as the Von Fry filament that elicited at least 3 positive tests out of 5 applications with two consecutive filaments. A positive test was defined as a sudden retraction of the foot, flinching, and / or foot licking induced by the filament.
[0349] Von Frey was administered for up to 5 days after unilateral CFA injection, depending on the experiment. The peptides were administered in a crossover schedule in five injections of each compound at sc (10 μL / g in PBS) and 2 μmol / kg to evaluate their efficacy in alleviating inflammatory pain. Statistical analysis was performed using GraphPad Prism 8.0. Dunnett's post-hoc test followed a two-way repeated measures ANOVA. The significance level was set at p<0.05.
[0350] result: On day 0, the baseline paw retraction response of mice was determined using a von Frye filament prior to intraplantar injection of 50 μL of CFA or physiological saline into the right hind paw.
[0351] Two to five days after CFA injection, mice were injected with PBS or 2.0 μmol / kg (10 μL / gram) of myr(C14)-NPEG4-(HWLKV)2, myr(C14)(unsaturated, trans)-NPEG4-(HWLKV)2, myr(C14)(unsaturated, trans)-NPEG4-(HWLKV)2, (C18)(diacid)-NPEG4-(HWLKV)2, (C16)-NPEG4-(HWLKV)2, and cholesterol-β-Asp-NPEG4-(HWLKV)2 via sc injection.
[0352] On all days, induced pain was tested using von Flei filaments before injection and at 2 and 5 hours after injection. Dunnett's post-hoc analysis followed separate two-way ANOVAs for each day of administration.
[0353] Injection of PBS did not induce any change in the pain retraction threshold, but myr(C14)-NPEG4-(HWLKV)2(mPD5) induced complete and very significant pain relief (Figure 18A). Similarly, myr(C14)(unsaturated, trans)-NPEG4-(HWLKV)2, myr(C14)(unsaturated, cis)-NPEG4-(HWLKV)2, and (C18)(diacid)-NPEG4-(HWLKV)2 induced very significant pain relief. Likewise, extension of the acyl chain to (C16)-NPEG4-(HWLKV)2 resulted in very significant pain relief (Figure 18B). Finally, cholesterol-β-Asp-NPEG4-(HWLKV)2 resulted in significant pain relief (Figure 18C).
[0354] conclusion This example demonstrates that in a CFA model of inflammatory pain, unsaturation can be introduced into the acyl chain, and additional acid groups can be converted to diacids. In addition, acyl chains with 14-16 carbon atoms and 18 carbon atoms (with diacids) appear to be equivalent in terms of efficacy. Finally, conjugation of a lipophilic aliphatic group (cholesterol in this case) via β-Asp demonstrates activity.
[0355] Example 17: Efficacy of mPD5 for the relief of sensitized heat pain In this experiment, the objective was to evaluate the mPD5 efficacy of sensitization to thermal pain induced by intraplantar injection of complete Freund's adjuvant (CFA).
[0356] material and method. Inflammatory pain (CFA model): Animals were acclimated to the laboratory for at least 60 minutes before the start of the experiment. The Hargreaves test was performed by applying radiant heat to the plantar surface of both hind feet. The response latency period was measured by automated reading (Ugo Basile, Italy). The baseline paw retraction latency period of both hind feet in response to radiant heat stimulation was performed before CFA injection, and no difference was observed between the two pre-selected groups. Inflammatory pain was induced by 10 unilateral injections of 50 μL of undiluted complete Freund's adjuvant (CFA) (F5881, Sigma) into the plantar surface of the right hind foot, while control mice were injected with the same volume of 0.9% saline (Bee Braun, Germany). All plantar injections were performed using an insulin needle (0.3 mL BD Micro-Fine) while the animals were under isoflurane anesthesia (2%) for up to 60 seconds. Three days after CFA injection, mice were placed in individual red cylinders (8 cm in diameter, 7.5 cm in height), and thermal hyperalgesia was confirmed by baseline readings of IR20. Three measurements were performed on each hind leg of each mouse. A positive test was defined as sudden withdrawal of the foot, flinching, and / or foot licking induced by infrared radiation. Measurements were performed before CFA injection and 3+4 days after CFA injection. On day 3, measurements were performed before treatment and at 1, 5, and 21 hours after treatment. Peptides and vehicles were administered at sc(10 μL / g) and concentrations of 0 μmol / kg or 10 μmol / kg. Statistical analysis was performed using GraphPad Prism 6.0. Bonferroni's post-hoc test followed a two-way repeated measures ANOVA. The significance level was set at p<0.05.
[0357] result: Three days after intraplantar CFA injection, thermal hyperalgesia was confirmed in the hind foot (ipsilateral) using the Hargreaves test. Following administration of 10 μmol / kg (10 μL / gram) myr-NPEG4-(HWLKV)2(mPD5) sc, we observed a very significant prolongation of the foot withdrawal latency period in the sensitized foot, while no significant change was observed in the contralateral (healthy) foot. Pain relief was not very pronounced at 5 hours and completely disappeared the following day (21 hours). Similar injections of PBS (vehicle) did not affect the foot withdrawal latency period in either foot (Figure 19).
[0358] Conclusion: This example demonstrates that mPD5 can completely alleviate thermal hypersensitivity observed in a CFA model of inflammatory pain without affecting thermal sensitivity in unaffected healthy feet. This extends the effects from hypersensitivity transmitted to touch to a significant modality of pain innervated by different subsets of nociceptors.
[0359] [Table 3] TIFF0007948598000018.tif242160
[0360] References ALFONSO, S., et al., Synapto-depressive effects of amyloid beta require PICK1. Eur J Neurosci, 2014. 39(7): p. 1225-33. ATIANJOH, F.E., et al., Spinal cord protein interacting with C kinase 1 is required for the maintenance of complete Freund’s adjuvant-induced inflammatory pain but not for incision-induced post-operative pain. Pain, 2010. 151(1): p. 226-34. BACH, A. et al. (2009). Design and synthesis of highly potent and plasma-stable dimeric inhibitors of the PSD-95-NMDA receptor interaction. Angew Chem Int Ed Engl 48, 9685-9689. BACH, A et al., 2012. A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. Proc Natl Acad Sci U S A, 109, 3317-22. BLANCHET, C. E. et al. J. Appl. Crystallogr. 2015, 48, 431. CHEN, S.R., et al., Nerve injury increases GluA2-lacking AMPA receptor prevalence in spinal cords: functional significance and signaling mechanisms. J Pharmacol Exp Ther, 2013. 347(3): p. 765-72. CLEM, R.L., V. Anggono, and R.L. Huganir, PICK1 regulates incorporation of calcium-permeable AMPA receptors during cortical synaptic strengthening. J Neurosci, 2010. 30(18): p. 6360-6. CONRAD, K.L., et al., Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. Nature, 2008. 454(7200): p. 118-21. DIXON, R.M., J.R. Mellor, and J.G. Hanley, Pick1-mediated glutamate receptor subunit 2 (GLUR2) trafficking contributes to cell death in oxygen / glucose deprived hippocampal neurons. Journal of Biological Chemistry, 2009. GANGADHARAN, V., et al., Peripheral calcium-permeable AMPA receptors regulate chronic inflammatory pain in mice. J Clin Invest, 2011. 121(4): p. 1608-23. GARRY, E.M., et al., Specific involvement in neuropathic pain of AMPA receptors and adapter proteins for the GluR2 subunit. Mol.Cell Neurosci., 2003. 24(1): p. 10-22. HANSEN S. et al. Journal of Applied Crystallography 2012, 45, 566. HANSEN S. et al. Journal of Applied Crystallography 2014, 47, 1469. HE, J., et al., PICK1 inhibits the E3 ubiquitin ligase activity of Parkin and reduces its neuronal protective effect. Proc Natl Acad Sci U S A, 2018. 115(30): p. E7193-E7201. JI, R.R., et al., Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci, 2003. 26(12): p. 696-705. KANDASAMY, R. and T.J. Price, The pharmacology of nociceptor priming. Handb Exp Pharmacol, 2015. 227: p. 15-37. KARLSEN, M.L. et al. 2015. Structure of Dimeric and Tetrameric Complexes of the BAR Domain Protein PICK1 Determined by Small-Angle X-Ray Scattering. Structure 23, 1258-70. LONG, J. F. et al. Supramodular structure and synergistic target binding of the N-terminal tandem PDZ domains of PSD-95. J. Mol. Biol. 2003, 327, 203-214. LORGEN, JO., PICK1 facilitates lasting reduction of GluA2 concentration in the hippocampus during chronic epilepsy. Epilepsy Res, 2017. 137: 25-32 LUSCHER, C. and R.C. Malenka, Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron, 2011. 69(4): p. 650-63. MADSEN, K.L. et al., 2005. Molecular determinants for the complex binding specificity of the PDZ domain in PICK1. Journal of Biological Chemistry 280, 20539-20548. MARCOTTE, D.J., et al., Lock and chop: A novel method for the generation of a PICK1 PDZ domain and piperidine-based inhibitor co-crystal structure. Protein Sci, 2018. 27(3): p. 672-680. MOLLER, A.R., Tinnitus and pain. Prog Brain Res, 2007. 166: p. 47-53. NISSEN et al. Design, synthesis, and characterization of fatty acid derivatives of a dimeric peptide-based postsynaptic density-95 (PSD-95) inhibitor. J. Med. Chem. 2015 Feb 12;58(3):1575-80. PEKER, S. and A. Sirin, Parallels between phantom pain and tinnitus. Med Hypotheses, 2016. 91: p. 95-97. TURNER et al. Administration of a novel high affinity PICK1 PDZ domain inhibitor attenuates cocaine seeking in rats. Neuropharmacology, 164(1), 2020, 107901. VANNESTE, S., W.T. To, and D. De Ridder, Tinnitus and neuropathic pain share a common neural substrate in the form of specific brain connectivity and microstate profiles. Prog Neuropsychopharmacol Biol Psychiatry, 2019. 88: p. 388-400. VIKMAN, K.S., B.K. Rycroft, and M.J. Christie, Switch to Ca2+-permeable AMPA and reduced NR2B NMDA receptor-mediated neurotransmission at dorsal horn nociceptive synapses during inflammatory pain in the rat. J Physiol, 2008. 586(2): p. 515-27. WANG, W., et al., Preserved acute pain and impaired neuropathic pain in mice lacking protein interacting with C Kinase 1. Mol Pain, 2011. 7: p. 11. WOLF, M.E. and C.R. Ferrario, AMPA receptor plasticity in the nucleus accumbens after repeated exposure to cocaine. Neurosci Biobehav Rev, 2010. 35(2): p. 185-211. WOOLF, C.J. and M.W. Salter, Neuronal plasticity: increasing the gain in pain. Science, 2000. 288(5472): p. 1765-9. ZHANG et al. Protein interacting with C alpha kinase 1 (PICK1) is involved in promoting tumor growth and correlates with poor prognosis of human breast cancer. Cancer Sci. 2010 Jun;101(6):1536-42.
Claims
1. A PICK1 inhibitor comprising a peptide portion and a non-peptide portion, wherein the peptide portion is a) General formula: X 1 X 2 X 3 X 4 X 5 A first peptide containing the amino acid sequence of; and b) General formula: X 1 X 2 X 3 X 4 X 5 a second peptide comprising the amino acid sequence of (In the formula, X 1 is H, N, F, or T, or does not exist; X 2 is W, S, E, or Y; or does not exist; X 3 is L, V, or I; X 4 is K, I, or R; and X 5 (is V) Composed of; The first peptide and the second peptide are selected from the group consisting of HWLKV (SEQ ID NO: 54), NSVRV (SEQ ID NO: 8), SVRV (SEQ ID NO: 44), and LRV. The aforementioned non-peptide portion is: c) A linker connecting the first peptide and the second peptide, and d) Lipophilic aliphatic group Includes, The lipophilic aliphatic group contains 12 to 22 carbon atoms, or the lipophilic aliphatic group is a sterol, The PICK1 inhibitor has the general structure of formula (I): 【Chemistry 1】 During the ceremony: Z is a single bond or a single amino acid; n is 2; p is 2. PICK1 inhibitor.
2. The PICK1 inhibitor according to claim 1, wherein the lipophilic aliphatic group is an aliphatic branched chain, an aliphatic unbranched chain, a saturated chain or an unsaturated chain, or an aliphatic ring.
3. The PICK1 inhibitor according to claim 1 or 2, wherein the lipophilic aliphatic group is cholesterol.
4. The aforementioned lipophilic aliphatic group is C 14 ~C 16 A PICK1 inhibitor according to any one of claims 1 to 3, wherein the PICK1 inhibitor is a fatty acid.
5. The PICK1 inhibitor according to any one of claims 1 to 4, wherein the lipophilic aliphatic group is selected from the group consisting of lauric acid, myristic acid, palmitic acid, margaric acid, and stearic acid.
6. The PICK1 inhibitor according to any one of claims 1 to 5, wherein the lipophilic aliphatic group is myristic acid.
7. The PICK1 inhibitor according to any one of claims 1 to 6, wherein the non-peptide portion comprises one amino acid selected from the group consisting of Asp, β-Asp, β-Ser, β-homo-Ser, and β-Lys.
8. A PICK1 inhibitor according to any one of claims 1 to 7, further comprising a detectable portion.
9. The aforementioned PICK1 inhibitor is myr-NPEG 4 - (HWLKV) 2 A PICK1 inhibitor according to any one of claims 1 to 8, having the structure of the above.
10. The PICK1 inhibitor is the PICK1 inhibitor according to any one of claims 1 to 9, having the general structure of formula (II). 【Chemistry 2】 (In the formula, n is 2, p is 2.
11. The PICK1 inhibitor is the PICK1 inhibitor according to any one of claims 1 to 10, having the structure of formula (IV), (V), (VI), or (VII). 【Transformation 3】 【Chemistry 4】 【Transformation 5】 【Transformation 6】
12. A micelle comprising the PICK1 inhibitor according to any one of claims 1 to 11.
13. A pharmaceutical composition comprising a PICK1 inhibitor according to any one of claims 1 to 11 or a micelle according to claim 12.
14. A PICK1 inhibitor, micelle, or pharmaceutical composition according to any one of claims 1 to 13 for use as a pharmaceutical.
15. A PICK1 inhibitor, micelle, or pharmaceutical composition according to any one of claims 1 to 14, for use in the prevention and / or treatment of diseases or disorders related to maladaptive plasticity.
16. The PICK1 inhibitor, micelle or pharmaceutical composition according to claim 15, wherein the disease or disorder associated with the maladaptive plasticity is pain, drug addiction, amyotrophic lateral sclerosis, epilepsy, tinnitus, migraine, cancer, ischemia, Alzheimer's disease, or Parkinson's disease.
17. The PICK1 inhibitor, micelle, or pharmaceutical composition according to claim 16, wherein the pain is mechanical or thermal allodynia or hyperalgesia, or the pain is inflammatory pain.
18. A PICK1 inhibitor according to any one of claims 1 to 11 or a micelle according to claim 12, for use in the diagnosis of a disease or disorder related to maladaptive plasticity.
Citation Information
Patent Citations
dimer inhibitor fatty acid derivatives of psd-95
JP2017501132A
